NIH Office of Technology Transfer (OTT) >> Abstract Search

Licensing & Royalties

Licensing Opportunities

Technology Abstracts

Devices/Instrumentation- Therapeutics:

Date	Ref. No.	Patent No.	Title
1/09	E-234-2008		Method for Predicting and Detecting Tumor Metastasis
1/09	E-275-2008 E-275-2008		Use of Mono-Amine Oxidase Inhibitors to Prevent Herpes Virus Infections and Reactivation from Latency
1/09	E-182-2008		Method of Treating Pneumoconiosis with Oligodeoxynucleotides
1/09	E-278-2007		Attenuated Salmonella as a Delivery System for siRNA-Based Tumor Therapy
1/09	E-295-2008		Novel Inhibitor of NF-kappa B Pathway
12/08	E-274-2008		Monoclonal Antibodies to the Tumor-Specific Antigen, Human ROR1
12/08	E-003-2008		A Novel, Non-Invasive and Therapeutically Useful High Throughput Technique to Isolate Highly Enriched Tumor Reactive Lymphocytes from Peripheral Blood - Potential Use in Adoptive Immunotherapy
12/08	E-310-2008		Discovery of Novel Pharmacophores Inhibiting the Growth of Mycobacterium tuberculosis
12/08	E-051-2008		A Novel and Efficient Technology for Targeted Delivery of siRNA
12/08	E-007-2008		Method of Promoting Hematopoietic Stem Cell Engraftment by Enhancement of CXCR4 Activity
12/08		7,025,961	Anti-Plasmodium Compositions and Methods of Use (E-004-2004)
12/08		7,365,160	Mutant Nuclear Orphan Receptor for Drug Metabolism Assays
11/08	E-256-1999		Methods for Accurately Measuring and Regulating Bound Adrenomedullin
11/08		7,349,834	Molecular Motors Powered by Proteins
11/08	E-187-2007		Indoline Compounds for the Treatment of Spinal Muscular Atrophy (SMA) and Other Diseases
11/08	E-056-2008		Retinal Pigment Epithelia-Enriched MicroRNAs to Prevent Cell-Differentiation, Proliferation, and Migration
11/08	E-145-2008		Compositions and Methods for Inhibition of Fat-Specific Protein 27
11/08	E-088-2006		Ectopic Thymidylate Synthase Accelerates the Development of Hyperplastic Foci and Adenomas in Pancreatic Islets
11/08	E-166-2007		Discovery of and Use of Fragments of DOC1 as Antiangiogenic and Antitumor Therapy
11/08	E-223-2006		Small-Molecule Modulators of the Thyroid-Stimulating Hormone (TSH) Receptor
11/08	E-174-2008		Therapeutic Targeting of CSN5, a Negative Regulator of p53 and p27, in Human Hepatocellular Carcinoma
11/08	E-169-2008		Methods for Using Interferon Gamma to Absorb Fluid From the Subretinal Space
11/08	E-013-2008		Human Monoclonal Antibodies Against Yersinia pestis
11/08	E-331-2007 E-331-2007		Viral Inactivation Using Crosslinkers and Detergents
11/08	E-256-2007		Radiation Induced and Targeted Chemotherapy
10/08	E-242-2007 E-328-2001		Use of CpG Oligodeoxynucleotides to Induce Epithelial Cell Growth
10/08	E-042-2008		Generation of Wild-Type Dengue Viruses for Use in Rhesus Monkey Infection Studies
10/08	E-183-2002		Method of Treating Infectious and Inflammatory Lung Disease with Suppressive Oligonucleotides
10/08	E-153-2002		Method of Treating and Preventing Infections in Immunocompromised Subjects with Immunostimulatory CpG Oligonucleotides
10/08	E-279-2007		Alpha 1-3 N-Acetylgalactosaminyltransferases with Altered Donor and Acceptor Specificities, Compositions, and Methods of Use
10/08	E-204-2007		Methods of Glycosylation and Bioconjugation
10/08	E-152-2004		Use of Suppressive Oligonucleotides to Treat Uveitis
10/08	E-280-2007		Beta 1,4-Galactosyltransferases with Altered Donor and Acceptor Specificities, Compositions and Methods of Use
10/08	E-145-2004		Monoclonal Antibodies Against Orthopoxviruses
10/08	E-159-2007		Monoclonal Antibodies Against Dengue and Other Viruses With Deletion in Fc Region
10/08	E-063-2008		Nanoparticles for Imaging and Treatment of Brain Tumors
10/08	E-250-2007		Induced Internalization of Surface Receptors
10/08	E-301-2003 E-301-2003		A Method with Increased Yield for Production of Polysaccharide-Protein Conjugate Vaccines Using Hydrazide Chemistry
10/08	E-066-2003		Monoclonal Antibodies That Bind or Neutralize Dengue Virus
10/08	E-089-2002		Dengue Tetravalent Vaccine Containing a Common 30 Nucleotide Deletion in the 3'-UTR of Dengue Types 1, 2, 3, and 4
10/08	E-230-2002		Catalytic Domains of [beta](1,4)-galactosyltransferase I Having Altered Donor and Acceptor Specificities, Domains That Promote In Vitro Protein Folding, and Methods for Their Use
9/08	E-343-2002		gammaPGA Conjugates for Eliciting Immune Responses Directed Against Bacillus anthracis and Other Bacilli
9/08		5,762,905 6,685,942	Human Neutralizing Monoclonal Antibodies to Respiratory Syncytial Virus and Human Neutralizing Antibodies to Respiratory Syncytial Virus
9/08	B-056-1994		Murine Monoclonal Antibodies Effective To Treat Respiratory Syncytial Virus
9/08		7,361,664	Vitamin D Receptor Antagonists for Treating Breast Cancer
9/08	E-202-2008		Inhibitors of the Plasmodial Surface Anion Channel as Antimalarials
9/08	E-027-2005		Novel Chemoattractant-Based Toxins to Improve Vaccine Immune Responses for Cancer and Infectious Diseases
9/08	E-324-2004		In Vitro Model for Hepatitis C Virion Production
9/08	E-149-2006		Compositions and Methods for Increasing Recombinant Protein Yields through the Modification of Cellular Properties
9/08	E-216-2007		Use of Razoxane for the Treatment of Alzheimer's Disease
9/08	E-211-2008		Fully Human Anti-Human NKG2D Monoclonal Antibody
9/08		7,261,900	Recombinant Modified Bacillus anthracis Protective Antigen for Use in Vaccines
9/08	E-163-2007		Bifunctional Compounds that Bind to Hormone Receptors
9/08		7,081,518	A Novel Recombinant Immunotoxin SS1P (anti-mesothelin dsFv-PE38): A Therapeutic Treatment for Lung Cancer and Other Mesothelin Expressing Cancers
9/08	E-323-2008		Matriptase Hypomorphic Mouse Model of a Human Ichthyosis
9/08	E-001-1996		Neutralizing Monoclonal Antibodies to Respiratory Syncytial Virus
9/08	E-123-2007 E-146-2004		Monoclonal Antibodies that Neutralize B. anthracis Protective Antigen (PA), Lethal Factor (LF) and Edema Factor (EF)
9/08	E-153-2005 E-153-2005		Prevention and Treatment of Multiple Sclerosis (MS) by Administering E-Selectin
9/08	E-053-2008		Aerosolized Vaccines
9/08	E-065-2008		Association of the ECHDCI/RNF146 Gene Region on Human Chromosome 6q with Breast Cancer Risk and Protection
9/08		7,419,817	Scalable Purification of AAV2, AAV4 or AAV5 Using Ion-Exchange Chromatography
9/08	E-178-1999 E-178-1999 E-178-1999		Human-Bovine Chimeric Respiratory Syncytial Virus (RSV) Vaccines
9/08	E-016-2008		Modified Sugar Substrates and Methods of Use
9/08	E-032-2008		Use of Saccharides Cross-Reactive with Bacillus anthracis Spore Glycoprotein as a Vaccine Against Anthrax
9/08		6,828,309	Use of Pentosan Polysulfate to Treat Certain Conditions of the Prostate
9/08	E-081-2008		Microfabricated Particles Useful as MRI Contrast Agents
9/08	E-147-2008		Cyclized NGR Peptide for Tumor Targeting
9/08	E-209-2007		Active Guidewire Visualization Device and System for MRI Guided Intervention
9/08	E-069-2008		Methods for the Detection and Treatment of Lung Cancer
8/08	E-227-2006		Methods of Preventing Tissue Ischemia
8/08		5,668,285	Total Synthesis of Northebaine, Normorphine, Noroxymorphone Enantiomers and Derivatives via N-Nor Intermediates
8/08	E-325-2007		Botulinum Toxoid
8/08	E-037-2008		Large Semi-Synthetic Human Antibody Domain Fragment Library
8/08	E-140-2008		Species-Independent A3 Adenosine Receptor Agonists
8/08	E-159-2008		Polyamine Compounds That Bind Tar RNA of HIV and Methods of Treating Viral Disorders
8/08	E-200-1990 E-200-1990 E-259-1994 E-259-1994 E-260-1994 E-062-1996 E-099-1996 E-154-1998 E-256-1998 E-256-1998		Enhanced T-cell Activation by Costimulation: A Potentially Novel Approach for the Prevention and/or Therapy of Cancer (Excluding Prostate Diseases and Melanoma) and for Infectious Diseases
8/08	E-072-2008		HIV Immunogen and Method of Making and Using Same
8/08	E-175-2008		Over-expression and Mutation of a Tyrosine Kinase Receptor FGFR4 in Tumors
8/08	E-043-2008		Cross-Reactive Neutralizing Human Domain Antibody Against HIV-1
8/08	E-332-2007		Small Molecule Inhibitors of c-Met
8/08	E-285-2006 E-285-2006 E-285-2006		New Tumor Endothelial Markers: Genes that Distinguish Physiological and Pathological Angiogenesis
8/08	E-249-2005		Methods of Treating and Preventing Renal Cancer using a Dimethane Sulfonate Compound
8/08	E-141-2003		Monoclonal Antibodies to HIV-1 Vpr
8/08	E-057-2002		Conjugates of Ligand, Linker, and Cytotoxic Agent and Related Compositions and Methods of Use
8/08	E-194-2008		Immunotoxins Made with Modified Cholix Toxin and Uses Thereof
8/08	E-262-2000 E-262-2000		SH2 Domain Binding Inhibitors (E-262-2000)
8/08	E-274-2003		2-Amino-O⁴-Substituted Pteridines: Improved Chemotherapy Adjuvants
7/08	E-282-2007		TGF-beta Gene Expression Signature in Cancer Prognosis
7/08	E-101-2004		Treatment of Alcoholism by Inhibition of the Neuropeptide Y Receptor
7/08	E-321-2006		Treatment of Skin Conditions Using DKK1
7/08	E-130-2007 E-130-2007 E-130-2007		Steroid Derivatives as Inhibitors of Human Tyrosyl-DNA Phosphodiesterase (Tdp1)
7/08	E-121-2008		Protein-tyrosine Phosphotase Inhibitors as Inhibitors of Human Tyrosyl-DNA Phosphodiesterase (Tdp1) and Methods of Treating Disorders
7/08	E-218-2007 E-218-2007		A2 Adenosine Receptor Agonists
7/08	E-211-2006		Therapeutic Application of Fatty Acid Amide Hydrolase Inhibitors
7/08	E-095-2008		A Prophylactic and Therapeutic for Preventing and Treating Tularemia by Rapid Activation of Host Cells and Antigen Recognition
7/08	E-150-2007		A Novel Therapeutic Strategy for the Treatment of Hyperpigmentation and Melanoma
7/08	E-229-2006		Novel O-GLcNAcase Inhibitor and Fluorogenic Substrate as a Tool for Diagnosing Type 2 Diabetes
7/08	E-154-2006		Use of Human Gamma Satellite Insulator Sequences to Prevent Gene Silencing and Allow for Long Term Expression of Integrated Transgenes
7/08	E-263-2004		A New Pot1 Variant Gene as a Diagnostic Biomarker for Hereditary Non-polyposis Colorectal Cancer
7/08	E-182-2007		Methods for Promoting Stem Cell Proliferation and Survival
7/08	E-233-2007		Tendon Stem Cells
7/08	E-276-2007		Neutralization of Hepatitis C Virus (HCV)
7/08	E-232-2008		Prolactin Receptor Antibodies as a Diagnostic Marker and Therapeutic Agent for Cancer
7/08		6,479,286	Methods and Compositions for Making Dendritic Cells from Expanded Populations of Monocytes and for Activating T Cells
6/08	E-245-2006		Novel Isoform of KCNH2 for the Treatment of Schizophrenia
6/08	E-292-2007		Immunotoxins with Deletions in Domain II that Remove Immunogenic Epitopes with Minimal Loss of Cytotoxic Activity
6/08	E-132-2007		The Combination of Anti-CD22 Immunotoxins with Standard Chemotherapeutic Agents on a Human Burkitt Lymphoma Cell Line
6/08	E-309-2006 E-309-2006 E-309-2006		Cell-Nanofiber Composite and Cell-Nanofiber Composite Amalgam Based Engineered Intervertebral Disc
6/08	E-198-2003		Construction of Recombinant Baculoviruses Carrying the Gene Encoding the Major Capsid Protein, VP1, From Calicivirus Strains (Including Norovirus Strains Toronto, Hawaii, Desert Shield, Snow Mountain, and MD145-12)
6/08	E-116-2005		Cell-Nanofiber Composite Based Engineered Cartilage
6/08	E-283-2003		Enzymatically-Active RNA-Dependent RNA Polymerase From a Human Norovirus (Calicivirus)
6/08	E-106-2007		Use of Amyloid Proteins as Vaccine Scaffolds
6/08	E-214-2003		Construction of an Infectious Full-Length cDNA Clone of the Porcine Enteric Calicivirus RNA Genome
5/08		6,320,022 7,101,548	Treatment and Diagnosis of Cancer, Diabetes and other Disorders Using Adrenomedullin Peptides and Antibodies
5/08	E-029-2008 E-029-2008		Human Papillomavirus microRNA Diagnostics and Therapeutics
5/08	E-096-2000		The Use of an Inducible Plasmid Vector Encoding for Active TGF-beta for the Treatment of Autoimmune Diseases
5/08		7,378,276	Method of Inducing Memory B Cell Development and Terminal Differentiation
5/08	E-080-2008		Human and Improved Murine Monoclonal Antibodies Against CD22
5/08	E-110-2006		Muramyl Dipeptide as a Therapeutic Agent for Inflammation
5/08	E-286-2006 E-286-2006		A Novel Growth Factor and Anti-Apoptotic Agent for Promoting Lung Development and Treating Lung Disease
5/08	E-129-2008		Synthetic Analogs of Juxtamembrane Domain of IGF-1 Receptor as Anti-Cancer Agents
5/08	E-316-2007		Method of Inhibiting ABCG2 and Related Treatments
5/08	E-265-2007		Telomerase Suppressor Compositions and Methods for Diagnosis and Treatment of Cancer
5/08	E-079-2008		Human Monoclonal Antibody Against Mesothelin
5/08	E-012-2008		C4'-Substituted-2-Deoxyadenosine Analogs and Methods of Treating HIV
5/08	E-265-1999		Inhibition of Cell Motility, Angiogenesis and Metastasis
4/08	E-036-2005		Identification of a Cell-Surface Co-Receptor that Mediates the Uptake and Immunostimulatory Activity of “D” Type CpG Oligonucleotides
4/08	E-055-2008		Substituted 3,6-diphenyl-7H-[1,2,4] triazolo[3,4-b] [1,3,4] Thiadiazines as Potent Inhibitors of PDE4A, PDE4B, and PDE4D
4/08	E-003-2007		Engineered Human Antibody Constant Domains (Nanoantibodies) as Scaffolds for Binders
4/08	E-116-2006 E-306-2006		Influenza Vaccines, Therapeutics, and Monoclonal Antibodies
3/08	E-154-2007		VEGF-B as a Therapeutic Agent for Neurodegenerative Disease
3/08	E-223-1998		P53 and VGEF Regulate Tumor Growth of NO2 Expressing Cancer Cells
3/08	E-064-2008		Epoxy-guaiane Cancer Inhibitors: New Class of Natural Products Isolated from the African Plant Phyllanthus englerii
3/08	E-023-2007		Nitrite Adjunctive Therapy to Enhance Efficacy of Reperfusion Therapy for Acute Myocardial Infarction
3/08	E-217-2007		N-Acetyl Mannosamine as a Therapeutic Agent
3/08	E-239-2007 E-239-2007		PSM Peptides as Vaccine Targets Against Methicillin-Resistant Staphylococcus aureus
3/08	E-100-2008		Cell Line PE, Developed From Mouse Skin Tumors, Demonstrates Unique Qualities
3/08	E-316-2003		Immunoglobulins with Potent and Broad Antiviral (HIV) Activity Based on scFv Joined by Flexible Linker to Fc
3/08	E-247-2002		Modulators of Nuclear Hormone Receptor Activity: Novel Compounds, Diverse Applications for Infectious Diseases, Including Anthrax (B. anthracis)
3/08	E-297-2007		Novel Adjuvant Therapy Using TIMP-2 Variants
2/08	E-055-2007 E-055-2007 E-055-2007 E-055-2007		Inhibiting HIV Infection Using Integrin Antagonists
2/08		7,144,918	Biologically Active Macrolides, Compositions and Uses Thereof
2/08	E-137-2006		Manganese Superoxide Dismutase VAL16ALA Polymorphism Predicts Resistance to Doxorubicin Cancer Therapy
2/08		7,196,074	Preparation and Use of Androgenic Compounds
2/08	E-245-2007		An Improved Non Viral System for Tumor Specific Suicide Gene Therapy
2/08	E-268-2007		A Fold-Back Diabody Format for Diphtheria Toxin-Based Immunotoxins That Can Increase Binding and Potency
2/08	E-017-2008		A Pharmacophore for Isatin-beta-Thiosemicarbazone Compounds with MDR1-Inverse Activity
2/08	E-172-2007 E-172-2007 E-172-2007		Collagen-Induced Platelet Aggregation Inhibitor from Mosquito Salivary Glands
2/08	E-019-2005		Synergistic Effect of TGF-beta Blockade and Immunogenic Agents on Tumors
2/08	E-186-2007		Papilloma Pseudovirus for Detection and Therapy of Tumors
2/08	E-162-2007		Ribosomal Protein S3 (RPS3), an Essential Component of NF-kappaB is a Novel and Selective Drug Target
2/08	E-208-2007		Eeyarestatins: Novel Deubiquitination Inhibitors for the Treatment of Drug-Resistant Cancers
2/08	E-315-2007		New Inhibitors of Multidrug Resistant Proteins Such As ABCG2
2/08	E-116-2004		Coacervate Microparticles Useful for the Sustained Release Administration of Therapeutics Agents
1/08		6,274,134	Antibodies and Polypeptides Specific to AAMP-1: Diagnostic and Therapeutic Uses Thereof
1/08	E-108-2007		Photosensitization by Nuclear Receptor-Ligand Complexes and Cell Ablation Uses Thereof
1/08	E-241-2006		A Drug Index to Quantify Harmful Drug Exposure in Older Adults
1/08	E-008-2008		Diagnosis and Treatment of Barrett's Esophagus and Associated Esophageal Adenocarcinoma
1/08	E-153-2007		Nitroxide Radical as a Treatment for Neurodegeneration
1/08	E-147-1999		Oligodeoxynucleotide and Its Use To Induce an Immune Response
12/07		6,727,079	cDNA Encoding a Gene BOG and its Protein Product
12/07	E-168-2007		Treatment for Chronic Inflammatory Disease and Cancer by Inhibition of MMP-1
11/07	E-302-2007		A Family of Small Molecules for Selective Inhibition of Wip1 Phosphatase
11/07	E-074-2007		Human T-box Transcription Factor Brachyury as a Target for Cancer Immunotherapy: Identification of Epitopes of Human Brachyury as Targets for T-cell Mediated Lysis of Tumors
11/07	E-061-2007		Diagnostic Ovarian Cancer Biomarkers
11/07	E-177-2006		A Novel, Inhibitory Platelet Surface Protein (TREM Like Transcript, TLT-1): New Target for the Treatment of Cancer, Infectious Diseases, Cardiac Diseases, and Platelet-Associated Disorders
11/07		5,583,002 5,556,763 5,889,143	A New Method for Determining Level of Immunosuppression in Humans
11/07	E-146-2007		Selenocysteine Mediated Hybrid Antibody Molecules
11/07	E-303-2003 E-135-2006		Inactivation of Enveloped Viruses and Tumor Cells for Infectious Disease and Cancer Vaccines
11/07		6,369,235 6,894,068	Novel Non-Nucleoside Agents for the Inhibition of HIV Reverse Transcriptase for the Treatment of HIV-1
10/07	E-039-2002		Potent HIV-1 Entry Inhibitors and Immunogens
10/07	E-187-2003		Quinoline Inhibitors of Retroviral Integrase
10/07		7,015,212	Thiazepine Inhibitors of HIV-1 Integrase
10/07	E-264-2006		Integrase Inhibitors for the Treatment of Retroviral Infection Including Human Immunodeficiency Virus-1
10/07	E-308-2005		Discovery of Tropolone Inhibitors of HIV-1 Integrase that can be Used for the Treatment of Retroviral Infection, Including AIDS
10/07	E-281-2003		Methods for Identifying Cathepsin G-Related Peptides as Modulators of Formylpeptide Receptors
10/07	E-104-2004 E-104-2004		Method for Inducing T-Cell Proliferation
10/07	E-084-2007		Use of HDAC Inhibitors for the Prevention and Cure for Brain Metastases of Cancers
10/07	E-237-2007		HIV-1 Integrase Inhibitors for the Treatment of Retroviral Infections
10/07	E-064-2005		Biomarkers for Tissue Status
10/07	E-224-2007		Novel Micro-RNA Sequence Transforms Non-Functional T-Lymphocytes to Highly Functional: Key to Improved Immunotherapy for the Treatment of Cancers
10/07	E-213-2007		Flexible, Polyvalent Antiviral Dendritic Conjugates for the Treatment of HIV/AIDS
10/07	E-068-2007		Novel Roles of a DNA Repair Protein, DNA-PKcs, in Obesity, Neurological Function, and Aging
9/07	E-072-2007		Optically Active Radio-labeled Reverse Transcriptase Inhibitors
9/07	E-161-2007		Treatment of Primary Tumors and Tumor Metastases with TNF-alpha Antagonists
9/07	E-126-2007 E-174-2007		Suppression of Allergic Asthma by Ascaris Antigens
9/07	E-200-2007		New and Improved Chemotherapy Adjuvants: Folate Based Inactivators of O⁶-alkylguanine-DNA alkyltransferase (alkyltransferase)
9/07	E-137-2005		Methods and Compositions for Treating FUS1 Related Disorders
9/07	E-050-2007		Methods of Determining the Prognosis of Hepatocellular Carcinoma
9/07		6,790,948 7,431,926	Tumor Suppressor Genes
9/07		7,256,256	Peptide Inhibitor of Cyclin Dependent Kinase 4 (CDK4) Derived from MyoD
8/07		6,939,547 7,108,981 7,235,365	Specific Binding Agents for KSHV vIL-6 that Neutralize a Biological Activity
8/07	E-223-2003		Improved Expression Vectors for Mammalian Use
8/07	E-282-2002		Methods and Compositions for Treating Diseases and Disorders Associated with Natural Killer T-Cells
8/07	E-233-2006 E-233-2006 E-233-2006		Design of Multi-functional RNA Nanoparticles and Nanotubes
8/07	E-013-2006		Antiviral Compounds with Broad Neutralization Capabilities
8/07	E-080-2006		A New Series of Thalidomide Analogs That Have Potent Anti-Angiogenic Properties
8/07	E-104-2006		Immunogenic Peptides and Methods of Use for Treating Prostrate and Uterine Cancers
8/07	E-179-2005		Isolation, Cloning and Characterization of New Adeno-Associated Virus (AAV) Serotypes
8/07	E-028-1999		Diagnostic and Therapeutic Methods of Detecting and Treating Cancers of Reproductive Tissues
8/07	E-215-2007		Methods for Determining Hepatocellular Carcinoma Subtype and Detecting Hepatic Cancer Stem Cells
8/07		5,877,179	Treatment for Cystic Fibrosis Cells and Other Reduced Cl^- Conductance Cells
8/07	E-306-2006 E-306-2006 E-306-2006 E-306-2006 E-306-2006		Avian Influenza Vaccine
8/07		6,685,933 7,235,232	Interferon Alpha Hybrids
8/07	E-249-2006 E-249-2006 E-249-2006		Device and Method for Protecting Against Coronary Artery Compression During Transcatheter Mitral Valve Annuloplasty
8/07	E-179-2007		Methods for Prevention and Treatment of Polyomavirus Infection or Reactivation (E-179-2007)
7/07	E-181-2007		Rational HIV Therapeutic Design
7/07	E-043-1997		Methods for Expression and Purification of Immunotoxins
7/07	E-164-2007		Compounds Binding to the N-Terminal Domains of STAT Proteins as Therapeutic Agents
7/07	E-059-2006		Method of Treating or Preventing Oxidative Stress-related Diseases (stroke and neurodegenerative diseases, wound healing and cardiovascular diseases)
7/07	E-089-2005		Benztropinamine Analogs as Dopamine Transport Inhibitors
7/07	E-265-2005		Modification of Recombinant Anti-tumor RNase (rapLR1) for Optimal Use in the Large Scale Manufacture of Stable and Potent RapLR1-Antibody Conjugates
7/07	E-151-2006 E-151-2006		Viral Entry or Replication Inhibitors
7/07	E-118-2005		A Gene Therapy to Treat Lung Cancer
7/07	E-149-2005		Methods and Materials for Identifying Polymorphic Variants, Diagnosing Susceptibilities, and Treating Disease
7/07	E-025-2007		Cytochrome P450 Inhibitors for Treatment of Cocaine-Induced Fetal Brain Injury
7/07	E-251-2005		Dysphagia Rehabilitation (Swallowing Recovery): Vibro-Tactile Stimulation Device and Method for Motor Control Recovery
7/07	E-288-2006		Cyclic Phosphopeptide Inhibitors of Protein Phosphatase 2C Delta, Wip1
6/07	E-088-2007		Zscan4: A Gene Critical for Early Embryonic Development
6/07	E-095-2007		A Gene Expression Signature Identifying Pro-Angiogenic Genes in Ovarian Tumor Endothelial Cell Isolates
6/07	E-098-2007		Synthetic Macrolides Inhibit Breast Cancer Migration
6/07	E-189-2006		Method for the Direct Detection and Quantitation of Asparagine Synthetase in Biological Samples
6/07	E-060-2007		A Gene Expression Profile that Predicts Ovarian Cancer Patient Response to Chemotherapy
6/07	E-117-2006		Diagnostic and Therapeutic Use of Brother of the Regulator of Imprinted Sites (BORIS) Alternative Splice Forms
6/07	E-101-2007		Methods for Prevention and Treatment of Polyomavirus Infection or Reactivation (E-101-2007)
6/07	E-144-2004		Monoclonal Antibodies That Bind or Neutralize Hepatitis B Virus
6/07	E-120-2007		A Novel Treatment for Non-Small Cell Lung Cancer Using Mesothelin-Targeted Immunotoxins
6/07	E-160-2006		Potent, Easy to Use Targeted Toxins as Anti-Tumor Agents
6/07	E-121-2007 E-121-2007		A Novel Discriminatory Small Peptide Inhibitor of Hsp90 Targeting Oncogenic Kinases
6/07		6,897,018	DLC-1 Gene Deleted in Cancers
6/07		5,167,956 5,725,857 6,632,928	Immunotoxin with in-vivo T cell Suppressant Activity
6/07		5,762,927 5,167,956 6,103,235	Methods of Inducing Immune Tolerance Using Immunotoxins
6/07		5,554,603	Orally Active Derivatives of 1,3,5(10)-estratriene
6/07		6,953,687	Vectors for Delivering Viral and Oncogenic Inhibitors
6/07	E-274-2000		Vibrio cholerae O139 Conjugate Vaccines
6/07	E-310-2001		Identification of Ovarian Cancer Tumor Markers and Therapeutic Agents
6/07		7,151,087 7,374,872	CC Chemokine Receptor 5 DNA, New Animal Models and Therapeutic Agents for HIV Infection
5/07		7,192,705 7,116,433	TMC1, a Deafness-Related Gene
5/07		7,193,053	Leu574 of HIF-1alpha as a Molecular Basis for Therapeutic Application
5/07	E-110-2004		New Maleiimide Anti-Phosphatase Inhibitors
5/07	E-140-2006		A Fullerene-based Anticoagulant
5/07	E-018-2005 E-018-2005 E-018-2005		Diagnosing and Treating Cancer Using beta-Catenin Splice Variants
5/07	E-133-2006 E-133-2006		New Compounds and Methods for the Treatment of Spinal Muscular Atrophy and Other Diseases
5/07		6,818,749 7,256,004	Humanized Anti-Carcinoma CC49 Monoclonal Antibodies
5/07		6,969,609	Enhanced T-cell Activation by Costimulation: An Effective Immunotherapy for Cancer and Infectious Diseases
5/07	E-016-2006 E-287-2004		Novel Diagnostics and Therapeutics for Various Hematologic Malignancies: Monoclonal Antibodies to Members of Fc receptor-like (FCRL) Proteins
5/07		5,491,130 5,849,701	Peptide Inhibitors of Fibronectin and Related Collagen-Binding Proteins
5/07	E-070-2005		Inhibitors of Ubiquitin E1
5/07	E-019-2000 E-019-2000 E-019-2000		Inhibition of ABC Transporters by Transmembrane Domain Analogs
5/07	E-082-2005 E-082-2005		Sipa-Gene and Sipa-1 Inhibitor for the Diagnosis and Treatment of Metastatic Cancer
5/07	E-307-2004		Aminoalkyl Substituted O⁶-Benzylguanine Derivatives as Inactivators of O⁶-Alkylguanine-DNA Alkyltransferase and Adjuvants for Chemotherapy
5/07	E-056-2004		STAMP, A Novel Cofactor and Possible Steroid Sparing Agent, Modulates Steroid-induced Induction or Repression of Steroid Receptors
4/07	E-181-2004		Preparation and Use of Androgenic Compounds: Nandrolone 17beta-carbonates
4/07	E-059-2007 E-059-2007		New Mouse T Cell Receptors as Potential Therapeutic Agents for the Treatment of Metastatic Cancer
4/07	E-098-2006		Structure of TIM Family Members
4/07	E-011-2007		Methods for Treating Autoimmune Inflammatory Disease by Blocking DR3-TL1A Interactions
4/07	E-315-2001		RAB38, a Target for Treatment of Melanoma and Pigmentation Disorders
4/07		6,753,317 6,916,905	Novel Dmt-Tic Analogues Specific for Delta- and Mu-Opioid Receptors
4/07	E-271-2006		A Novel DNA Vaccine for the Treatment of Malignancies Expressing Immature Laminin Receptor Protein
4/07	E-205-2006 E-205-2006		Preparation of (R,R)-Fenoterol and (R,R)-or (R,S)-Fenoterol Analogues and Their Use in Treating Congestive Heart Failure
4/07	E-314-2005		Apparatus for Brachytherapy
4/07	E-239-2005		Method for Promoting Stem Cell Proliferation and Survival
4/07	E-014-2002		Neural Crest-Melanocyte cDNA Based Microarray Analysis for Human Skin Pigmentation Research
4/07	E-121-2002		Identification of Anti-HIV Compounds Inhibiting Virus Assembly and Binding of Nucleocapsid Protein to Nucleic Acid
3/07		7,217,811 7,189,812	A Fertility Test to Detect Ovarian Autoimmune Disease Using Human Recombinant MATER Protein
3/07	E-126-2006		Novel Benzindole Based Compounds for HIV Therapy
3/07	E-148-2003		Genes Expressed in Prostate Cancer and Methods of Use
3/07	E-105-2003		Cloning and Characterization of an Avian Adeno-Associated Virus and Uses Thereof
3/07	E-314-2003 E-314-2003 E-314-2003		Identification and Isolation of the Receptor for Pigment Epithelium-derived Factor (PEDF)
3/07	E-024-2006		Microdialysis Probe for Accessing Tissue in-vivo
3/07	E-297-2006		CCR5-Specific Human Monoclonal Antibodies
3/07	E-304-2006		Enhanced Function of Gene Modified T-Cells: Identification of T-Cell Receptors (TCR) with Altered Amino Acid Sequence
3/07	E-074-1999 E-117-1995		Cyanovirins and Related Conjugates, Compositions, Nucleic Acids, Vectors, Host Cells, Methods of Production and Methods of Use for Microbicide Development
3/07	E-035-2005		Potent Activation of Antigen Presenting Cells by the Hepatitis A Virus Cellular Receptor 1 and Its Role in the Regulation of Immune Responses
3/07	E-172-2005		Methods of Treating Conditions Characterized by Unwanted or Excessive Presynaptic Neuronal Activity or Secretion
3/07	E-323-2004		Arylthioindole Tubulin Polymerization Inhibitors and Methods of Treating or Preventing Cancer Using Same
2/07	E-317-2004		Metal Chelators and Target-Moiety Complexes for Imaging
2/07	E-130-2001		Broadly Cross-Reactive Neutralizing Antibodies against Human Immunodeficiency Virus Selected by ENV-CD4-CO-Receptor Complexes
2/07	E-070-2007		Human Cancer Therapy Using Engineered Anthrax Lethal Toxin
2/07	E-138-2006		Highly Soluble Pyrimido-Dione-Quinoline Compounds: Small Molecules that Stabilize and Activate p53 in Transformed Cells
2/07	E-267-2006		A Novel Combination of CXCR-4 Antagonist T22 with Conventional Immunotherapy Improves Treatment Efficacy in Established Tumors
2/07		6,562,347	Methods and Compositions of Chemokine-Tumor Antigen Fusion Proteins as Cancer Vaccines
2/07		6,790,657 7,226,780	Lentivirus Vector System
1/07	E-132-2006 E-132-2006 E-132-2006		A New Method for Improving the Therapeutic Efficacy of L-Asparaginase in Multiple Types of Cancer
1/07	E-305-2006		Macrocyclic Grb2 SH2 Domain-Binding Inhibitors: New Anti-cancer and Anti-angiogenic Therapeutic Agents
1/07		5,616,471	Methods for Assaying Hair Follicle Growth and Development
1/07		5,420,033	Epithelial Cell Line Expressing a Cystic Fibrosis Phenotype
1/07	E-183-2004		Enriched Natural Killer Cells for Adoptive Infusion Cancer Therapy
1/07	E-234-2005 E-234-2005		Novel Benztropine Analogs for Treatment of Cocaine Abuse and Other Mental Disorders
12/06	E-295-2005		Novel Treatments for Autoimmune Neuroinflammatory Diseases including Multiple Sclerosis
12/06	E-125-2006		Extracellular Matrix/Metastasis Modifier Genes as a Method for Characterization and Prevention of Metastatic Tumor
12/06	E-014-2007		Peptide and Peptidomimetic Inhibitors of Smoothened Protein as Anti-neoplastic Agents
12/06	E-311-2006 E-311-2006		Chitosan as a Universal Vaccine Adjuvant, Antigen Depot and Cytokine Depot
12/06	E-347-2004		ARH3, a Therapeutic Target for Cancer, Ischemia, and Inflammation
12/06	E-252-2001		HIV Entry Inhibitor
11/06	E-186-2006		Second Generation Nitric Oxide-releasing Non-steroidal Anti-inflammatory Drugs Possessing a Diazeniumdiolate Group (NONO-NSAIDs)
11/06	E-200-1998		Methods for Treating Drug-Resistant HIV-1 Infection
11/06			Anti-H5N1 Influenza Activity of the Antiviral Protein Cyanovirin
10/06	E-027-2006		PDE11A as a Novel Therapeutic Target for Inherited Form of Cushing Syndrome and Endocrine Tumors
9/06	E-200-2006		Mammalian Cell Surface Display of Fvs for Rapid Antibody Maturation
9/06	E-271-2005		Novel Treatment of Vascular Cognitive Impairment
9/06	E-017-2006		Organic Thiophosphate Antiretroviral Agents
9/06		6,635,614	Use of LCAT to Reduce Cholesterol and Prevent Atherosclerosis
9/06	E-262-2003		Methods for Enhancing Beta Cell Function in Diabetes
09/06	E-186-2005		Human Protein Tissue Inhibitor of Metalloproteinases-2 (TIMP-2) Derived Anti-Angiogenic Peptides
9/06	E-212-2004		Diagnostic and Therapeutic Use of SPANX-N Genes in Cancer and Fertility
9/06		7,084,239	Cancer Peptides of NY-ESO-1/CAG-3
8/06		7,051,737	Mucus Shaving Apparatus for Endotracheal Tubes
8/06		6,706,729	Novel Thioesters And Uses Thereof
8/06	E-336-2001		Amyloid Beta is a Ligand for FPR Class Receptors
8/06	E-086-2006		Hybrid T-Cell Receptors for the Development of Improved Vaccines
8/06	E-275-2002 E-275-2002		Adoptive T-Cell Transfer After Lymphodepletion Promotes Tumor Regression
8/06	E-329-2000		Novel Acylthiol Compositions and Methods of Making and Using Them
8/06	E-042-2006		Complement Regulatory Gene Variants as Predictive Tests for Age-related Macular Degeneration (AMD)
8/06			Use of Grape Skin Extracts as Anti-Cancer Agents
8/06	E-166-2006		A Novel Small Protein Antibiotic
8/06	E-201-2006		Diagnostic and Therapeutic Strategies for Metastatic Hepatocellular Carcinoma by Targeting Osteopontin
8/06	E-180-2006		Neutralizing Monoclonal Antibodies to Botulinum neurotoxin A
8/06	E-074-2005		The Mucus Slurper: A Novel Device to Keep the Endotracheal Tube (ETT) Free of All Mucus, Without Suctioning
8/06	E-340-2004 E-340-2004		Adoptive Immunotherapy with T Lymphocytes Engineered for Enhanced Survival
7/06	E-017-2004		Methods and Compositions Related to GHS-R Antagonist
7/06	E-335-2005		Fluorescent Imaging and Photodynamic Treatment of Tumors
7/06	E-136-2006		Method for Expanding Allodepleted Antigen Specific T Cells
6/06	E-090-2004		Radio-Activated Boron-Nitride Nanotube-Antibody Conjugates for Cancer Therapy and Diagnostics
6/06	E-165-2006		Diamidine Inhibitors of Tdp1 as Anti-Cancer Agents
6/06	E-091-2004		Ultrasonic Waves with Nanovessels or Tethered Nanotube/Monoclonal Antibody Composites for Cancer Therapy
6/06	E-010-2005		Generation of Regulatory T Cells for Immunotherapy
6/06	E-097-2006		Use of Tetracyclines as Anti-Cancer Agents
6/06	E-122-2006		Agonist Epitopes for Renal Cell Carcinoma
6/06	E-336-2005		Novel Human IGF-1 Specific IGF-I and IGF-II Cross-Reactive Human Monoclonal Antibodies as Potential Anti-tumor Agents
6/06	E-108-2005		Treatment of Inflammatory Bowel Disease (IBD) using NF-KB Decoy Polynucleotides
6/06	E-003-2005		Treatment and Prevention of Inflammatory Bowel Disease (IBD) using Mutant and Chimeric IL-13 Molecules
6/06		6,982,168	Immortal Human Prostate Epithelial Cell Cultures as a Prostate Cancer Model
5/06	E-031-2003		Immunogenic Epitopes for Fibroblast Growth Factor-5 (FGF-5) Presented by HLA-A3 and HLA-A2
5/06	E-039-2004 E-039-2004 E-039-2004 E-039-2004		Peptide Inhibitors of HIV-1 Integrase Useful for the Treatment of Retroviral Infection and HIV
5/06	E-114-2003		Methods and Compositions for the Inhibition of HIV-1 Replication
5/06	E-265-2003		Methods for Inhibiting HIV and Other Viral Infections by Modulating Ceramide Metabolism
5/06	E-075-2003		Use of Cripto-1 as a Biomarker for Neurodegenerative Disease and Method of Inhibiting Progression Thereof
5/06	E-106-1994		Novel Bis-Acridones As Anti-Tumor Agents: Potential For Treating Drug Resistant Tumors
5/06	E-106-2006		T-cell Receptor Recognizing Renal Cell Carcinoma
5/06		6,680,176	Identification of Candidate Ligands which Modulate Antigen Presenting Cells
5/06	E-305-2005		Potent Pharmacophoric Delta- and Mu-Opioid Receptor Antagonists and Conversion of Endomorphin Mu-Opioid Agonists to Antagonists
5/06	E-200-2005		Insect Cell Production of Recombinant Adeno-Associated Virus that Produce Cytotoxic Gene Products and Applications for Solid Tumor Therapy
5/06	E-139-2005		Identification of a Novel Folliculin Interacting Protein, FNIP-1
5/06	E-196-2004		Bone Morphogenetic Variants, Compositions and Methods of Treatment
5/06	E-094-2006		Preparation of a Peptide Targeted Human RNase, RGD-Eosinophil Derived Neurotoxin (RGD-EDN) To Specifically Target Tumor Vasculature
5/06	E-090-2006 E-090-2006		Adoptive Immunotherapy with Autologous Natural Killer Cells
5/06	E-176-1998		Anti-Notch-1 Monoclonal Antibodies for Inducing Cellular Differentiation and Apoptosis
3/06		6,984,379	Gene Therapy by Administration of Genetically Engineered CD34+ Obtained by Cord Blood
3/06	E-319-2005		Methods of Treating Cancer Using Pyridine Carboxaldehyde Pyridine Thiosemicarbazone Radiosensitizing Agents
3/06	E-262-1999		Monoclonal Antibodies Which Specifically Bind to the Ligand Hepatocyte Growth Factor (HGF) and are Useful in the Treatment of Cancer
3/06	E-128-2005		Rapid Methods for Human Artificial Chromosome (HAC) Formation
3/06	E-312-2005		Immunogenic Peptides and Methods of Use for Treating and Preventing Cancer
3/06	E-254-2003		Treatment of Pulmonary Hypertension (PH) Using Nitrite Therapy
3/06	E-263-2003		Immunogenic T Cell Targets in Autoimmune Hepatitis and Methods of Use
3/06	E-051-2006		Deoxyhypusine Hydroxylase
3/06	E-208-2003		TNF-alpha Converting Enzyme Inhibitory Agents and Stimulatory Agents
3/06	E-184-2001		Modified Growth Hormone
2/06		6,100,555 6,989,263	The CCHC Zinc Fingers of the Retroviral Nucleocapsid Protein Comprises a New Target Useful in Identification and Evaluation of Anti-HIV Therapeutics
2/06		6,060,458	Oligodeoxyribonucleotides Comprising O⁶-Benzylguanine and Their Use
2/06	E-065-2002		ELISA Assay of Serum Soluble CD22 to Assess Tumor Burden/Relapse in Subjects with Leukemia and Lymphoma
2/06		6,294,322	Multideterminant Peptides That Elicit Helper T-Lymphocyte Cytotoxic T-Lymphocyte and Neutralizing Antibody Responses Against HIV-1
2/06	E-025-2006		Anti-Viral Griffithsin Compounds, Compositions, and Methods of Use
2/06	E-218-2005		Methodology for Large Scale Manufacture of Stable Disulfide-Conjugated Antibody-Ribonuclease
2/06	E-175-2004		Rapid Anti-Depressant Response Produced by Low Dose Treatment with Anti-Muscarinic Drugs
2/06	E-296-2004		Novel Form of Interleukin-15, Fc-IL-15, and Methods of Use
2/06		5,976,541	Potent Peptide for Stimulation of Cytotoxic T Lymphocyte Specific for the HIV-1 Envelope
2/06	E-106-2005		Identification of Biomarkers by Serum Protein Profiling
2/06		6,040,334	Use of Inhibitors of 3-Hydroxy-3-Methylglutaryl Coenzyme A Reductase as a Modality in Cancer Therapy
1/06	E-298-2004		Transcytosis of Adeno-Associated Viruses
1/06	E-163-2005		Intraperitoneal Injection of Pseudovirions Carrying a Toxin Leads to Significantly Reduced Tumor Size
1/06	E-014-1991		Pharmaceutical Compositions and Methods for Preventing Skin Tumor Formation and Causing Regression of Existing Tumors
1/06	E-067-1995		Treatment of Hyperproliferative Epithelial Skin Diseases by Topical Application of Hydroxylated Aromatic Protein Cross-Linking Compounds
12/05	E-058-2005		Synthesis of Indenoisoquinoliniums and Methods of Use
12/05	E-142-2005		A Single Ribozyme to Catalyze both Trimming and Transacting Catalysis - Potential Therapeutic for HPV Infection and Cervical Cancer
12/05	E-133-2005		Genomic Nucleic Acid Sequence for Cyanovirin-N and Signal Peptide Thereof
12/05	E-253-2005		Methods and Compositions for the Inhibition of SARS-CoV Replication Propagation and Transmission
12/05	E-323-2003		Minimally Immunogenic Variants of SDR-Grafted Humanized Antibody CC49 and Their Use
12/05	E-003-2006		Antibodies and Immunotoxins that Target Human Glycoprotein NMB
12/05	E-142-1990		Autotaxin: Motility Stimulating Protein Useful in Cancer Diagnosis and Therapy
12/05	E-205-1999		Bisubstrate Inhibitors of Acetyltransferases
11/05	E-217-2005		Antibodies Against Insulin-Like Growth Factor II and Uses Thereof
11/05	E-104-2005		Furin Inhibitors and Alpha-Defensin for Preventing Papilloma Virus Infection
11/05	E-051-2005		Identification of a Fusion/Entry Receptor for Human Herpesvirus-8
11/05	E-192-2004		Compositions and Methods for Diagnosis and Treatment of Chemotherapy-Resistant Neoplastic Disease
11/05	E-272-2002 E-272-2002		Serine Protease Inhibitors
10/05	E-081-2001 E-081-2001 E-081-2001		Zebularine, A Stable and Orally Active Inhibitor of Cytosine DNA Methyltransferase Capable of Reactivating Dormant Tumor Suppressor and Inhibiting Tumor Growth
10/05	E-065-2005		Novobiocin Analogues as Anticancer Agents
10/05		5,272,146 5,441,941	1,2-Dihydroellipticines with Activity Against CNS-Specific Cancer Cell Lines
10/05	E-167-1997		The Use of Nitroxides in the Prophylactic and Therapeutic Treatment of Cancer Due to Genetic Defects
10/05		6,428,788	Compositions and Methods of Specifically Targeting Tumors
10/05		6,984,517	AAV5 Vector and Uses Thereof
10/05	E-262-2005		Mutated Pseudomonas Exotoxins with Reduced Antigenicity
9/05	E-211-2005		Inhibitors of the Protein Kinase Chk2 to Abrogate Apoptosis and Sensitize Cancer Cells to DNA Targeted Therapies
9/05	E-121-2005		Polymer-linked Pseudomonas Exotoxin Immunotoxin
9/05	E-087-1996		Heterologous Boosting Immunizations
9/05	E-181-1999		A Combined Growth Factor-Deleted and Thymidine Kinase-Deleted Vaccinia Virus Vector for Cancer Therapy
9/05	E-095-2000		Amelioration of Inflammatory Arthritis Targeting the Pre-ligand Assembly Domain (PLAD) of Tumor Necrosis Factor Receptors
9/05		5,217,953 5,565,424 6,630,124	Cancer Therapy Using Vasoactive Intestinal Peptide Antagonists
9/05	E-144-2005		Soluble Fragments of the IGF1R Ectodomain
9/05	E-327-2004		A New Approach Toward Macrocyclization of Peptides
9/05	E-105-2002		Regulation of INS (3456) P₄ Signaling by a Reversible Kinase/Phosphatase and Methods and Compositions Related Thereto
9/05	E-243-2002 E-243-2002		Recombinant Vaccinia Viruses Expressing IL-15 and Methods of Using the Same
9/05	E-312-2003		Methods for Treating Viral-Associated Tumors with LFA-1 Inhibiting Statins
9/05		6,943,191	Disubstituted Lavendustin A Analogs and Pharmaceutical Compositions Comprising the Analogs
9/05	E-291-2003		New Building Blocks for DNA Binding Agents
9/05	E-244-1997 E-244-1997		Antitumor Macrocyclic Lactones / Vacuolar-Type (H+)-ATPase-Inhibiting Compounds and Uses Thereof
9/05		6,136,992	Novel 2-Alkoxy Estradiols and Derivatives Thereof
9/05	E-060-2002		DNA-Binding Polyamide Drug Conjugates
9/05	E-315-2003		SH2 Domain Binding Inhibitors (E-315-2003)
8/05		7,163,818	Bacteriophage Having Multiple Host Range
8/05	E-318-2000		Method for Determining Sensitivity to a Bacteriophage
8/05	E-236-2002		Design of a Novel Peptide Inhibitor of HIV Fusion that Disrupts the Internal Trimeric Coiled-coil of gp41
8/05	E-302-2004		A32 Monoclonal Antibody Fusion Protein for Use as HIV Inhibitors and Vaccines
8/05	E-140-2005		Induction of C/EBPalpha and Uses Thereof
8/05		5,861,156	Methods of Delivering Agents to Target Cells
8/05	E-235-2004		Inhibition of SMAD-Signaling Leads to Enhanced Insulin Production and Better Glucose Control: A Potential Therapy for Diabetes and Associated Complications Due to Hyperglycemia
8/05	E-092-2004		Anti-Marinobufagenin Antibodies and Methods for Their Use
8/05	E-047-2005		North-2'-Deoxy-Methanocarbathymidines as Antiviral Agents Against Poxviruses
8/05	E-046-2005		A Novel Interleukin-12 (IL-12) Inducing Protein Isolated from Toxoplasma gondii Inflammatory Profilin (TGIP)
8/05	E-083-2002		Use of Discoidin Domain Receptor 1 (DDR1) and Agents that Affect the DDR1/Collagen Pathway
8/05	E-180-2005		Scytovirin Domain 1 (SD1) Related Polypeptide
8/05	E-137-2003		Vaccines and Methods of Treating Drug-Resistant HIV-1 and Hepatitis B Viruses
8/05	E-155-2005 E-155-2005 E-155-2005 E-155-2005		Immunogenic Peptides From Human Papillomavirus Type 16 E2
8/05	E-131-2000		Methods for Reducing Tumor Growth and Metastasis by Inhibiting MCP-1 Activity
7/05		5,792,752 5,902,794	Use of 8-C1-cAMP as Anticancer Drug
7/05	E-208-2005		Anti-CD30 Antibodies that Bind to Intact CD30 but not to Soluble CD30
7/05		7,052,907	Adult Human Dental Pulp Stem Cells in vitro and in vivo
7/05		6,812,246	Aminoflavone Prodrug
7/05	E-075-2004 E-075-2004 E-075-2004		Methods for the Identification and Use of Compounds Suitable for the Treatment of Drug Resistant Cells
7/05	E-033-2004		Multipotent Postnatal Stem Cells From Human Periodontal Ligament and Uses Thereof
7/05	E-018-2003		Postnatal Stem Cells and Uses Thereof
6/05	E-320-2001		Compositions and Methods for Inhibiting Vascular Channels and Methods of Inhibiting Proliferation
6/05	E-135-2002 E-135-2002		Novel Anti-CD30 Antibodies and Recombinant Immunotoxins Containing Disulfide-Stabilized Fv Fragments
6/05		6,153,421 7,201,911	Cloned Genomes Of Infectious Hepatitis C Virus And Uses Thereof
6/05	E-018-2005		Method of Diagnosing and Treating Cancer Using beta-Catenin Splice Variants
6/05	E-138-2005		Infectious Particle Composition and Methods of Use Thereof
6/05	E-339-2004		Framework Residue Substituted Humanized COL-1 Antibodies and Their Use
6/05	E-188-2004		Therapeutic Delivery of Nitric Oxide From Novel Diazeniumdiolated Derivatives of Acrylonitrile-based Polymers
6/05	E-106-2004		Compositions Comprising T Cell Receptors and Methods of Use Thereof
6/05	E-158-2005		Identification of H2-Db and HLA-A2 Specific CD8 Epitopes from Human KDR/VEGFR-2 that Inhibit Angiogenesis by Vaccination
6/05	E-121-2004		A New Antiviral Pathway that is Responsible for Viral Clearance: Modulation of ADAR1 Activities Enhance Antiviral Therapies and Virus Infection of Tissue Culture Systems
6/05	E-271-2003 E-271-2003		Epitopes of Ebola Virus Glycoproteins Useful for Vaccine Development
6/05	E-302-2003		Inhibiting IL-13 Receptor-Expressing Cancer Cells with Anti-IL-13 Receptor Immunotoxin and Alkylating Agents
6/05	E-043-2005		Cell Culture System for Efficient Expression of Self-Replicating Norwalk Virus
5/05	E-069-2005		Mammary Gland Differentiation by 2-Methoxyestradiol
5/05	E-199-1999		Mycolactone and Related Compounds
5/05	E-279-2004		Treatment of Human Viral Infections (Resveratrol)
5/05	E-281-2004		Treatment of Human Viral Infections (Imatinib)
5/05	E-280-2004		Treatment of Human Viral Infections (Proteosome Inhibitors)
5/05	E-282-2004		Treatment of Human Viral Infections (Farnesyl Transferase Inhibitors)
5/05	E-330-2004		Synthesis of Phosphocholine Ester Derivatives and Conjugates Thereof
5/05	E-245-2004		Methods of Reducing the Activity and Concentration of an Eph Receptor Tyrosine Kinase
5/05	E-272-2003		Analogs of Thalidomide as Potential Angiogenesis Inhibitors
5/05	E-295-2002		Lepirudin Adsorbed to Catheter
4/05		7,303,754	MVA Expressing Modified HIV envelope, gag, and pol Genes
4/05	E-263-2002 E-263-2002		Peptide Inhibitors of Yersinia Phosphatase (YopH) as Potential Treatments Against Plague
4/05	E-356-2003		Chimeric HIV/SIV Polypeptide Trimers as HIV/AIDS Vaccine Candidates
4/05	E-190-2002		Identification of Novel Birt-Hogg-Dubé (BHD) Gene
4/05	E-150-2001		Use of a Promoter of T-cell Expansion and an Inducer of CD40 Stimulation in the Treatment or Prevention of a Pathologic State
4/05		6,916,843	Endothelial Protective Actions of Cytochrome P450 Epoxygenase-derived Eicosanoids
4/05	E-176-2003		Antibodies Against the Amino Terminus Region of Circumsporozoite Protein Prevent the Onset of Malaria
4/05	E-160-2004		Methods for Inhibiting or Treating Cancer
4/05	E-226-2004		Metastasis Suppressor Gene on Human Chromosome 8 and Its Use in the Diagnosis, Prognosis and Treatment of Cancer
4/05	E-104-1999		T-Cell Receptor Alternate Reading Frame Protein, (TARP) and Uses Thereof
4/05	E-343-2004		Use of Targeted Bone Marrow Cell Infiltration to Induce Pigmentation and Hair Growth in Skin
4/05	E-107-2005		Methods for Tumor Treatment Using Dendrimer Conjugates
4/05	E-117-2005		Aminoglycosides and Ribosome Inhibitors as Inhibitors of Tyrosyl-DNA-Phosphodiesterase
4/05		6,797,492	Method for Reducing the Immunogenicity of Antibody Variable Domains
4/05		6,255,104 6,342,392 6,737,251	Nucleotide and Deduced Amino Acid Sequences of a New Tumor Gene, Int6
4/05	E-333-2004		HIV Neutralization by Structure-Based Enhancements of CD4-Molecular Mimicry
4/05	E-358-2004		Triptolide to Induce Immunotolerance
4/05	E-127-2005		Composition and Methods for Diagnosis and Treatment of Metastatic Disease
4/05	E-072-2005		Inhibition of Proteosome Function to Potentiate the Proapoptotic and Antitumor Activity of Cytokines
4/05	E-318-2004		Regulation of ATG7 Beclin 1 Program of Autophagic Cell Death by Caspase-8
4/05		5,104,977 5,656,587 5,705,477	Compositions of Transforming Growth Factor Beta (TGF-beta) Which Promotes Wound Healing and Methods for Their Use
3/05	E-105-2004 E-105-2004		Minimally Immunogenic Germline Sequence Variants of COL-1 Antibody and Their Use
3/05	E-001-2005		Carbohydrate-Encapsulated Gold Nanoparticles as Novel Anti-Metastatic Agents
3/05	E-281-1999 E-281-1999		Tyrosyl-DNA Phosphodiesterases (TDP) and Related Polypeptides, Nucleic Acids, Vectors, TDP-Producing Host Cell, Antibodies and Methods of Use
3/05		5,610,053	Chromatin Insulator Protecting Expressed Genes of Interest for Human Gene Therapy or Other Mammalian Transgenic Systems
3/05	E-079-2005		Inhibition of Human Papillomavirus Type 16 and 18 E6 and E7 Oncogene Expression by E6 and E7-specific siRNAs
3/05	E-215-2004		CpG Oligonucleotide Prodrugs
3/05	E-076-2004		An Epitope-Enhancement of Human CD4 HIV Epitope
3/05	E-101-2005		Karyotypic Complexity as a Determinant of Anti-Cancer Drug Activity
3/05	E-251-2004		Broadly Cross-Reactive HIV-1 Neutralizing Human Monoclonal Antibodies
3/05	E-037-2005		Dimer Inhibitory Peptides of CXCR4 as a Possible Novel Therapy for Cancer
3/05		4,942,184	Water-Soluble, Antineoplastic Derivatives of Taxol
3/05	E-196-1998		Cannula for Pressure Mediated Drug Delivery
3/05	E-160-2002		Tryptophan as a Functional Replacement for ADP-ribose-arginine in Recombinant Proteins
3/05	E-010-2004		Modulating P38 Kinase Activity
2/05	E-328-2004		Methods for Treating Active Uveitis
2/05	E-025-2003 E-025-2003		Methods for Prophylaxis and Treatment of HER-2/neu Tumors
2/05	E-204-2001		Rapid, Efficient In Vivo Site-Directed Mutagenesis Using Oligonucleotides
2/05	E-355-2004		Compositions and Methods for the Treatment of Immune-Related Disease
2/05	E-094-2003		A Novel, Preservative-Free Steroid Formulation for Use as an Anti-Inflammatory
2/05	E-226-2003		Novel Potent Monoamine Oxidase Inhibitors
2/05	E-248-2004		A3 Adenosine Receptor Agonists
1/05	E-237-2004		Closed-Circuit Flow Obturator for Laparoscopy Port
1/05	E-102-2004		Treatment of Inappropriate Immune Responses
1/05	E-244-2004		The UBE2G2 Binding Domain in the Ubiquitin Ligase GP78 and Methods of Use Thereof
1/05	E-131-2002		A Method of Treating Inflammatory Bowel Disease (IBD)
1/05	E-130-2004		Novel Methods for Reducing Inflammation and Treating Diseases such as Parkinson’s and Alzheimer’s Disease
1/05	E-259-2003		Anti-Proliferative Activity of an Unexpected mTOR Kinase Inhibitor
1/05	E-116-2003		Immunogenic Peptides for the Treatment of Prostate and Breast Cancer
1/05	E-172-2004		Novel Compounds and Methods for Treating Alzheimer’s and Related Diseases
1/05	E-287-2004 E-287-2004		Mabs to IRTA2 for Use in Diagnosis and Therapy of IRTA-Expressing Cancers
1/05	E-123-2001 E-124-2001		Peptide Agonists of Prostate-Specific Antigen and Uses Thereof
1/05	E-208-2002		Applications for the HMGN1 Pathway
1/05	E-084-2003		Detection of Antigen-Specific T Cells and Novel T Cell Epitopes by Acquisition of Peptide/HLA-GFP Complexes
1/05	E-191-2003		Eosinophil-Derived Neurotoxin, an Antimicrobial Protein with Ribonuclease Activity, is an Immunostimulant
1/05	E-051-2003		Recombinant Immunotoxin and Use in Treating Tumors
1/05	E-331-2002		Activation of Recombinant Diphtheria Toxin Fusion Proteins by Specific Proteases Highly Expressed on the Surface of Tumor Cells
1/05	E-073-2003 E-073-2003		Protein Kinase C Inhibitor, Related Composition, and Method of Use
12/04			Adoptive Immunotherapy with Enhanced T-Lymphocyte Survival
12/04	E-095-2004		Novel Compounds That Release Both Nitric Oxide (NO) and Nitroxyl (HNO) As Pharmacological Agents
12/04	E-332-2004		The Use of Rabbits with Defined Immunoglobulin Light Chain Genes (C_kappa b allotypes) to Optimize Production of Chimeric and Humanized Monoclonal Antibodies for Therapeutic, Imaging and Diagnostic Applications
12/04	E-004-2005		Human Monoclonal Antibodies Against Hendra and Nipah Viruses
12/04		6,855,314	AAV5 Vector for Transducing Brain Cells and Lung Cells
12/04		6,468,524	AAV4 Vector and Uses Thereof
12/04		7,238,473	TTP as a Regulator of GM-CSF mRNA Deadenylation and Stability
12/04	E-299-2004		Vaccines Against Crimean-Congo Hemorrhagic Fever
12/04	E-257-2004		Modulating Expression of the Metastasis Suppressor MxA
11/04	E-233-2004 E-233-2004		Anti-HIV Peptide Secreting Bacteria: Therapeutics and Methods of Use
11/04	E-178-2004 E-178-2004		Infectious Clone of Human Parvovirus B19 and Methods of Use
10/04	E-256-2004		Inhibitors of HIV Ribonuclease H Antiviral Properties
10/04	E-062-2003		Use of Smad3 Inhibitor in the Treatment of Fibrosis Dependent on Epithelial to Mesenchymal Transition as in the Eye and Kidney
10/04	E-220-1993 E-039-2003		Method for Inhibiting Angiogenesis and Combinatorial Therapy for Protein Signaling Diseases
10/04	E-059-2004		Multimeric Protein Toxins to Target Cells Having Multiple Identifying Characteristics
10/04	E-342-2004		Mouse Monoclonal Antibody (4G11) Against Insulin-Like Growth Factor I Receptor
10/04	E-272-2004		Protozoan Derived Antagonist of CCR5
10/04		7,303,751	Anti-Plasmodium Compositions and Methods of Use (E-049-2004)
10/04	E-070-2000		Inhibition of Smad3 to Prevent Fibrosis and Improve Wound Healing
9/04	E-311-2003		Use of Protein Kinase C Delta Inhibitor, Specifically Rottlerin, Alone or in Further Combination with Staurosporine, in the Treatment of Metastatic Epithelioid Melanoma
9/04	E-312-2000 E-312-2000 E-312-2000		Hybrid Adeno-Retroviral Vector for the Transformation of Cells (E-312-2000)
8/04		6,734,014	Methods and Compositions for Transforming Dendritic Cells and Activating T Cells
8/04		6,723,551 7,271,002	Production of Adeno-Associated Viruses in Insect Cells
8/04	E-007-2004		Adduct Compounds of Pyrrolobenzodiazepinones, Compositions Comprising the Same and Methods Related Thereto
8/04	E-211-2003		A Combined Immunosuppressive Therapy Consisting of Glucocorticoid and rIL-2
8/04		6,696,436	B-Homoestra-1,3,5(10)-trienes as Modulators of Tubulin Polymerization
8/04	E-106-2003		Griffithsin, Glycosylation-Resistant Griffithsin, and Related Conjugates, Compositions, Nucleic Acids, Vectors, Host Cells, Methods of Production and Methods of Using
8/04	E-254-2003		Methods of Use of Nitrite Therapy
8/04	E-074-2004		Methylation Inhibitor Compounds
8/04	E-056-2003 E-056-2003		Human Neuronal Cells for Therapeutic Uses
8/04	E-013-2003		Activation of Nerve Growth Factor Receptor Trophic Functions
7/04	E-090-2003		Vaccine Peptide Derived from XAGE-1 to Prevent Tumor Growth
6/04	E-035-2004 E-035-2004 E-035-2004 E-035-2004		Stem Cell Factor (SCF) Stimulates Neural Stem Cell Migration to Sites of Brain and Spinal Cord Injury
6/04	E-325-2002		Antibodies That Bind POTE and Uses Thereof
6/04		5,635,599 6,011,002	Circularly Permuted Ligands and Circularly Permuted Fusion Proteins
6/04	E-335-2003 E-335-2003		Mechanisms for Improving the Breadth of the Immune Response to Diverse Strains and Clades of HIV
6/04	E-150-2004		A Peptide that Elicits Neutralizing Antibodies Targeting the HIV Co-Receptor CCR5
6/04	E-165-2004		SARS Coronavirus MVA Vaccines and Therapy
6/04	E-278-2003		Interferon-Alpha SARS Treatment
6/04	E-016-2004		Methods for Inhibiting Proinflammatory Cytokine Expression Using Ghrelin
6/04	E-334-2003 E-334-2003 E-334-2003		Enhanced Sensitivity ELISA for SARS Diagnostic
6/04		5,652,223 5,981,712	DNA Encoding CAI Resistance Proteins and Uses Thereof
6/04	E-228-2003 E-228-2003		Soluble SARS Coronavirus Spike Protein (S Protein)
5/04	E-004-02/0 E-004-2002		Cloning and Mutational Analysis of the Hyperparathyroidism-Jaw Tumor Syndrome (HPT-JT) Gene
5/04	E-125-2002 E-125-2002		Methods of Diagnosing Potential for Developing Hepatocellular Carcinoma or Metastasis and of Identifying Therapeutic Agents
5/04		7,332,645	IL-21 Critically Regulates Immunoglobulin Production
5/04	E-002-2002		Materials and Methods for Inhibiting Wip1
5/04	E-321-2002		BASE, a New Cancer Gene, and Uses Thereof
5/04	E-321-2000		Novel Antisense Oligonucleotides Targeting Folate Receptor Alpha
5/04	E-040-2004		Methods for Producing Biliverdin
4/04	E-048-2004 E-048-2004 E-048-2004		Construction of a Recombinant Mammalian Expression System for the Production of Human TGF-beta 1 and Members of TGF-beta Superfamily Cytokines
4/04	E-061-2003		Long Term Retrievable Venous Filter
4/04	E-073-2004		Reduction of HIV-1 Replication by a Mutant Apolipoprotein B mRNA Editing Enzyme-Catalytic Polypeptide-like 3G (APOBEC3G)
4/04	E-196-2002		Bromotyrosine-Derived Inhibitors of Mycothiol-S-Conjugate Amidase
4/04	E-008-2004		Therapeutic Administration of the Scrambled Anti-Angiogenic Peptide C16Y
4/04		7,052,904	Hybrid Adeno-Retroviral Vector for the Transformation of Cells (E-258-1998)
4/04	E-326-2002		Triplex Hairpin Ribozyme
4/04	E-069-2004		Formylpeptide Receptor (FPR) as a Target for Anti-Malignant Glioma Therapy
4/04	E-142-2002		Reagents to Produce Purified Human 14-3-3 Zeta and 14-3-3 Epsilon as Glutathione-S-Transferase Fusion Protein
4/04	E-133-2004		Carbohydrate-Encapsulated Quantum Dots For Cell-Specific Biological Imaging
4/04		6,676,657	Endoluminal Radiofrequency Cauterization System
4/04	E-068-2004		MVL, an Antiviral Protein from a Cyanobacterium
3/04	E-008-1996		C-C Chemokines That Inhibit Retrovirus Infection
3/04	E-125-2001		Novel Spore Wall Proteins and Genes From Microsporidia
3/04	E-231-2002		Deazaflavin Compounds and Methods of Use Thereof
3/04	E-218-2003 E-218-2003		Method and Apparatus for Bioweapon Decontamination
3/04	E-146-1999 E-163-1993 E-135-1989 E-216-2000		BL22, An Immunotoxin That Shows Efficacy in Clinical Trials in Treating Patients with Chemotherapy-Resistant Hairy Cell Leukemia, and Ha22, a Newly Engineered Immunotoxin, Which Shows Improved Cytotoxic Activity Over BL22
3/04	E-028-2004 E-028-2004 E-028-2004		A Novel Interferon-Gamma-Inducible Secretoglobin
3/04	E-146-1999 E-135-1989		LMB-2, An Immunotoxin That Shows Efficacy in Phase I Clinical Trials in Treating Patients with Chemotherapy-Resistant Hairy Cell Leukemia and Other Hematologic Malignancies
3/04	E-277-2003		Stimulation or Inhibition of Gamma Delta T-Cells to Promote or Inhibit Bone Growth
3/04	E-181-2002		Methods and Devices for Intramuscular Stimulation in Dysphonia
3/04		6,699,842	Dominant Negative Deletion Mutants Of C-Jun And Their Use In The Prevention And Treatment Of Cancer
2/04		5,935,575	Interleukin-4 Stimulated T-Lymphocyte Cell Death for the Treatment of Autoimmune Diseases, Allergic Disorders and Graft Rejection
2/04	E-173-2003		Interference with c-maf Function in Multiple Myeloma Retards Tumor Adherence and Progression and Decreases Expression of Integrin beta7, C-C Chemokine Receptor 1, and Cyclin D2
2/04	E-244-2002		Glioma-Selective Polypeptides, Alone or Coupled to a Therapeutic/Diagnostic Agent, Compositions Comprising Same, and Uses Thereof
2/04	E-286-2002 E-286-2002 E-286-2002		Aerosolized Capreomycin for Inhibition of Pulmonary Tuberculosis
2/04	E-250-2002 E-250-2002		Safer Attenuated Virus Vaccines with Missing or Diminished Latency of Infection (E-250-2002)
2/04	E-037-2001		Use of IL-13 Inhibitors to Prevent Tumor Recurrence
2/04	E-091-2003		Methods for the Treatment of Parkinson's Disease and Other alpha-synucleinopathies
2/04		5,460,941 5,510,473 5,707,811	Homologous DNA Recombination
2/04		6,083,503 5,989,546	Interleukin-2 Stimulated T-Lymphocyte Cell Death for the Treatment of Autoimmune Diseases, Allergic Disorders and Graft Rejection
1/04	E-084-1999		Methods for Inhibiting Chaperone Proteins
1/04		6,632,808	Inhibitors of Amyloid Formation
1/04		5,276,059	Inhibition of Diseases Associated with Amyloid Formation
1/04		6,211,149 6,355,610	Inhibitors of Formation of Protease Resistant Prion Protein
1/04	E-324-2003		Streptococcus Lipoprotein Antigens
12/03	E-022-2003		Discovery of Novel Inhibitors of HIV-1 Integrase and/or RNase H That Can Be Used for the Treatment of Retroviral Infection Including AIDS
12/03	E-189-2003		Thalidomide Analogs
12/03		6,596,690	Vasostatin as Marrow Protectant
12/03	E-024-2002		Methods and Compositions of Defensin-Antigen Fusion Proteins and Chemokine-Antigen Fusion Proteins as Vaccines for Tumors and Viral Infection
12/03	E-276-2001		Improved Endogenous Opioid Anti-Nociception with Reduced Neurodegeneration, Hyperalgesia, Allodynia and Tolerance
12/03	E-109-2000		Pain Control by the Selective Local Ablation of Nociceptive Neurons
12/03	E-081-2002		A Mouse Model for Human Osteoarthritis
12/03	E-276-2003		HIV-Dependent Expression Vector
12/03	E-019-2004		Construction of Replication-Competent Chimeric Simian Immunodeficiency Virus (SIV) Human Immunodeficiency Virus Type 1 (HIV-1) Viruses that Replicate Using HIV-1 Reverse Transcriptase and Integrase (IN): A Model System for Development and Testing of Antiviral Agents for the Treatment of HIV-1 Infection
12/03	E-297-2002		Methods of Preparing Lymphocytes that Express Interleukin-2 and Their Use in the Treatment of Cancer
12/03	E-227-2002		Targeting of the Hepatitis A Cellular Receptor to Treat Renal Cancer
12/03	E-191-2001		gp64 Pseudotyped Vectors and Uses Thereof
11/03	E-337-2001		Efficient Inhibition of HIV-1 Viral Entry Through a Novel Fusion Protein Including CD4
11/03	E-253-2003		Cytotoxic Indeno- and Isoindenoisoquinoline Compounds
11/03	E-224-2003		Inhibition of Retrovirus Gene Expression by PSF
11/03	E-072-2001		Identification of New Small RNAs and ORFs
11/03		4,810,777 5,567,681 5,643,876	Antimicrobial Magainin Peptides
11/03		6,875,855	Molecular Diagnosis of Disseminated Candida albicans Infection Using Hemoglobin-Response Gene
11/03	E-169-2003		Geldanamycin Derivatives with Methyl Substituted Hydrogen Atom at the N22 Position as Anti-Cancer Agents
11/03	E-064-2003		Degradation and Transcriptional Inhibition of HIF-2alpha Protein by 17-AAG
11/03	E-038-2003		High Efficiency Single Stranded Homologous Recombination in Host Cells Deficient for Mismatch Repair
11/03	E-253-2002		Compositions and Methods for Detecting Abnormal Cell Proliferation
11/03	E-008-2001		Compositions and Methods for Enhancing Differential Gene Expression
11/03	E-537-1983 E-970-1997		Leukoregulin, An Antitumor Lymphokine, and Its Therapeutic Uses
11/03		5,629,454 5,869,666 5,840,728	Conformationally Locked Nucleoside Analogues and Conformationally Locked Nucleoside Analogs As Antiherpetic Agents
11/03	E-090-1994 E-090-1994 E-200-1994 E-200-1994 E-200-1994 E-200-1994 E-201-1994 E-201-1994 E-201-1994 E-201-1994		Novel Antimalarial Compounds, Methods of Synthesis Thereof, Pharmaceutical Compositions Comprising Same, and Methods of Using Same for Treatment and Prevention of Malaria
11/03	E-055-2002		Novel Stable Anti-CD22 Antibodies
11/03	E-342-2002 E-342-2002		beta-Defensins as Activators of Dendritic Cells and Vaccine Carrier
11/03	E-285-2002		Lutozmyia longipalpis Polypeptides and Methods of Use
11/03	E-083-2003		Intracellular Trapping of Radionuclides by Enzyme-Mediated Reduction
11/03	E-223-2002		Factors That Bind Intestinal Toxins
10/03	E-294-2002		A New Target for Angiogenesis and Anti-Angiogenesis Therapy
10/03	E-019-2003 E-001-2003 E-001-2003		Methods and Materials for Controlling Stem Cell and Cancer Cell Proliferation and Differentiation
9/03	E-145-2002		Sigma-2 Receptor Agonists Inhibit HIV Infection and Replication in Lymphocytes
9/03	E-016-2000 E-016-2000 E-016-2000		Cloning and Characterization of VIAF in Several Organisms
9/03		5,622,861	Hepatitis A Virus Receptor And Methods Of Use
9/03	E-224-2002		Novel Anti-Tumor and Anti-Fungal Compounds Isolated from Plants of the Genus Aniba
8/03		7,364,719	Vasopressor Peptide Derived From Adrenomedullin and Methods of Its Use
8/03	E-063-2003		Rapamycin Resistant T Cells and Therapeutic Uses Thereof
8/03	E-143-2002 E-143-2002		Method for the Treatment of Multiple Sclerosis
8/03	E-301-2002		Cycloxygenase Inhibition with Nitroxyl
8/03	E-329-2001		Licensing/CRADA Opportunity to Develop Therapeutic Uses for the Newly Identified Cardiac Precursor Cells Named "SPOC" Cells
8/03	E-327-2002		Inhibition of HIV-1 Replication by the Ribonuclease, Recombinant Angiogenin
8/03	E-273-2002		Nitroxyl Progenitors in the Treatment of Heart Failure
8/03	E-225-2003		Protection Against Vertical Transmission of Pathogenic Infections
8/03	E-329-2001		Stem Cells that Transform to Beating Cardiomyocytes
7/03	E-251-2002 E-251-2002		Structurally Rigid Dopamine D3 Receptor Selective Ligands as Cocaine and Methamphetamine Abuse Therapeutics
7/03	E-049-2001		Long-Acting Insulinotropic Peptides and Uses Thereof
7/03	E-281-2001		Oral Treatment of Hemophilia
7/03	E-190-2000 E-190-2000		Methods and Compositions for Inhibiting HIV-Coreceptor Interactions
7/03	E-173-2001		HTLV-1 p30^II and p12^I Proteins as Therapeutic Targets in HTLV-1 Infected Individuals
6/03		6,664,263 6,541,483	Imidazoacridones with Anti-Tumor Activity
6/03	E-113-2002		Method for Preparing 17alpha-acetoxy-11beta-(4,N,N-dimethylaminophenyl)-19-norpregna-4,9-diene-3,20-dione, Intermediates Thereof, and Methods for the Preparation of Such Intermediates
6/03		7,329,502	Zap70 Protein Expression as a Marker for Chronic Lymphocytic Leukemia (CLL)
6/03	E-304-2000		ABCA13 Nucleic Acids and Proteins, and Uses Thereof
5/03	E-097-2003		Triggering Receptors Expressed in Myeloid Cells (TREM) Like Transcript (TLT-1), A Novel Inhibitory Receptor of Platelets and Uses Therefore
5/03	E-240-2002		HTLV-1 Cell Binding and Inhibition
5/03	E-175-2002 E-076-2003 E-175-2002		Method of Treating Ischemia/Reperfusion Injury with Nitroxyl Anion Donors
5/03		7,087,589	Methanocarba Cycloalkyl Nucleoside Analogues
5/03	E-256-2002		17-AAG Treatment of Diseases Sensitive to c-KIT Down Regulation
5/03		6,673,338 6,949,530	Preparation and Medical Uses of Novel Nitric Oxide Releasing Imidates, Amidines Derived Therefrom, and Enamines
4/03	E-003-2003		Amplification and Overexpression of Septin9 MLL Septin-Like Fusion (MSF) and Methods Related Thereto
4/03	E-278-98/1		Benzoylalkylindolepyridinium Compounds and Pharmaceutical Compositions Comprising Such Compounds
4/03	E-017-2002		Scytovirins and Related Conjugates, Antibodies, Compositions, Nucleic Acids, Vectors, Host Cells, Methods of Production and Methods of Using Scytovirin
4/03	E-191-2002		Chondropsin-Class Antitumor V-ATPase Inhibitor Compounds, Compositions and Methods of Use Thereof
4/03	60/447,497		Method and Materials for Promoting Migration of T-Cells to the Vasculature of a Tumor
4/03	E-219-2002 E-219-2002 E-219-2002		Methods of Inhibiting Metastasis or Growth of a Tumor Cell
4/03	E-060-2000 E-060-2000		sFRP and Peptide Motifs That Interact with sFRP and Methods of Their Use
4/03		7,081,452 7,163,935	Scorpionate-Like Pendant Macrocyclic Ligands, Complexes and Compositions Thereof, and Methods of Using Same
4/03	08/933,003 09/555,229		Spontaneous Breathing Apparatus and Method
3/03	E-261-2000		Optimization of Cardiac Contraction by Novel Human Kinase Mediated Differential Phosphorylation of Myosin
3/03	E-138-2001		Use of Semenogelin in the Diagnosis, Prognosis, and Treatment of Cancer
3/03		5,844,075 6,537,560	gp100 Cancer Antigens
3/03	E-189-2002		Novel Cyclic Polyamines That Release Nitric Oxide in a Biphasic Manner
3/03	E-176-2002		Modified Oligonucleotides and Methods of Use Thereof
3/03	E-052-2002 E-052-2002		Tumor Suppressor Gene Polypeptides and Related Nucleic Acids, Host Cells, Compositions, and Methods of Use in Inhibition of Cell Growth, Modulation of Gene Expression, and Enhancement of Immune-Response Inducing Effect of a Vaccine
3/03		6,368,828	Attenuated and Dominant Negative Variant cDNAs of STAT6: STAT6b and STAT6c
3/03	E-056-2002		Grafting of a Murine Antibody Onto a Human Framework
2/03	E-008-2003		Scavenger Receptor BI Targeting for the Treatment of Infection, Sepsis and Inflammation
2/03	E-259-2002		Compositions and Methods for Inhibiting Group B Streptococcal-Induced Pulmonary Hypertension in Neonates
1/03		6,808,877	Ligands for FPR Class Receptors that Induce a Host Immune Response to a Pathogen or Inhibit HIV Infection
1/03	E-239-02/0		Minimally Immunogenic Variant of Humanized COL-1 Antibody Against Carcinoembryonic Antigen (CEA)
1/03	E-144-02/0 E-144-02/1		Novel Broadly Cross-Reactive HIV Neutralizing Human Monoclonal Antibodies Selected from Fab Phage Display Libraries Using a Novel Strategy Based on Alternative Antigen Panning and Novel Broadly Cross-Reactive HIV-1 Neutralizing Human Single-Chain Antibodies Derived from X5 by DNA Shuffling and Alternating Antigen Panning
12/02	E-235-2000		Improving Chemotherapy by Increased Killing of Tumor Cells and Protection of Normal Cells Through p38 Kinase Inhibition
12/02	E-090-2002		Assays for Assembly of Ebola Virus Pseudoparticles Relevant to Antiviral Therapy and Vaccines
12/02	E-238-2001		A Metastasis Suppressor Gene on Human Chromosome 8 and Its Use in the Diagnosis, Prognosis, and Treatment of Cancer
12/02	E-013-2002		Humanized Anti-TAG 72 CC49 for Diagnosis and Therapy of Human Carcinomas
12/02	E-156-1999		Pyrimidine Phosphorylase as a Target for Imaging and Therapy
11/02	E-296-2001		Alleviating Symptoms of Th2-Like Cytokine Mediated Disorders by Reducing IL-13 Receptor-Expressing Cells in the Respiratory Tract
11/02	E-198-2001		Use of a Histone Deacetylase Inhibitor to Increase the Entry of an Adenoviral Agent into a Cell
11/02	E-216-00/2		PEGylation of Linkers Improves Antitumor Activity and Reduces Toxicity of Immunoconjugates
11/02	E-080-2002		Modified Defensins and Their Use
11/02	E-292-2001		Use of Mx GTPases in the Prognosis and Treatment of Cancer
11/02	E-005-2002		New Gene Expressed in Prostate Cancer and Methods of Use
11/02	E-196-2001		Use of Interferon-Inducible 2',5'-Oligoadenylate-Dependent RNase in the Diagnosis, Prognosis, and Treatment of Prostate Cancer
11/02		5,359,078 5,482,954 5,498,620	Signal Transduction Inhibitor Compounds in Clinical Trials as Cancer Therapeutics
11/02	E-263-2001		Bone-Forming Composition, Methods for Making and Methods of Use
11/02	E-317-2001		Discovery of Novel Inhibitors of HIV-1 Integrase That Can Be Used for the Treatment of Retroviral Infection Including AIDS
10/02	E-356-2001		Four Chimpanzee Monoclonal Antibodies that Neutralize Hepatitis A Virus
10/02	E-039-99/0 E-039-99/2		A Novel Chimeric Protein For Prevention And Treatment Of HIV Infection
9/02	E-300-2001		New Tumor Suppressor Gene, p28ING5
9/02	E-048-2002		Antiproliferative Actions of Human IGF Binding Protein-3 Mutants That Do Not Bind IGF-I or IGF-II
8/02	E-096-02/0		An Obligate Domain-Swapped Dimer of Cyanovirin with Enhanced Anti-Viral Activity
8/02	E-321-2001		Methods and Compositions for Antagonizing Septic Shock
8/02		5,942,230 6,197,528	Retinoids Can Increase the Potency of Anti-Cancer Immunotoxins
8/02	E-247-2001		Methods of Diagnosing and Treating Schizophrenia
8/02	E-165-2001		Maxp1, A New Tumor Suppressor Regulated by Ras
8/02	E-053-02/0		Methods and Compositions for the Promotion of Hair Growth Utilizing Actin-Binding Peptides
7/02	E-129-2001		Mutated Anti-CD22 Antibodies with Increased Affinity to CD22-Expressing Leukemia Cells
7/02	E-137-2002		Methods for Treating Cancer in Humans Using IL-21
7/02		6,756,399	Use of Lipoxygenase Inhibitors and PPAR Ligands as Anti-Cancer Therapeutic and Intervention Agents
5/02	E-344-01/0		The Ovachip: A Clinically Useful cDNA Array for Differential Diagnosis of Ovarian Cancer
5/02	E-206-2000 E-206-2000		Enhanced Distribution of Therapeutic Agents After Local Delivery
5/02	E-113-1999		Sol Fusin: Use of GP64-6HIS to Catalyze Membrane Fusion
5/02	E-225-2001		MRP8, A Member of the ABC Transporter Superfamily Highly Expressed in Breast Cancer, and Uses Thereof
5/02	E-151-01/0		Method of Promoting Engraftment of a Donor Transplant in a Recipient Host
5/02	E-176-01/0		Magnetic Labeling of Cells Using Transfection Agents
5/02	E-284-01/0		Specific Inhibition of Gene Expression by Small Double Stranded RNAs
4/02	E-174-2000		Effect of COMT Genotype on Frontal Lobe Function
4/02	E-051-02/1		Methods for Using Modulators of Extracellular Adenosine or an Adenosine Receptor to Enhance Immune Response and Inflammation
4/02	E-323-2000		Activated Dual Specificity Lymphocytes and Their Methods of Use
4/02	E-017-00/0		Compositions and Methods for the Diminution or Elimination of Various Cancers
4/02	E-099-01/0		Mitochondrial Topoisomerase I
3/02	E-253-2000		Artificial Chromosomes That Can Shuttle Between Bacteria, Yeast, and Mammalian Cells
3/02	E-079-01/0		Treatment of Pain Based on Parathyroid Hormone-2 (PTH2) Receptors
3/02	E-328-2001		Use of CpG Oligodeoxynucleotides to Encourage Angiogenesis
3/02	E-360-2001		Generation and Use of Tc1 and Tc2 Cells
2/02	E-242-01/0		Strategies to Destabilize the Active HIV-1 Protease Dimer Resulting in Stable Monomer Formation
2/02	E-114-01/0		Methods of Generating Human CD4+ Th2 Cells
2/02	E-059-2001 E-059-2001		Transforming Growth Factor-Beta (TGF-Beta) Antagonist Selectively Neutralizes "Pathological" TGF-Beta
2/02	E-335-01/0		Methods of Generating Human CD4+ Th1 Cells
2/02	E-130-01/0		Novel Broadly Reactive HIV-Neutralizing Human Monoclonal Antibody Against Receptor-Induced Epitope on gp120
2/02	E-143-1999		Novel Anti-Thrombin Peptide from the Salivary Gland of Anopheles albimanus
2/02	E-265-98/0 E-265-98/1		Identification of Compounds that Potentiate the Activity of Muscarinic Potassium Channels
2/02	E-122-2001		Anti-Arthropod Vector Vaccines, Methods of Selecting, and Uses Thereof
2/02	E-218-01/0		Identification of DNA Sequence Motifs that Suppress the Immune Response to CpG DNA
2/02	E-215-01/0		Use of Sterically Stabilized Cationic Liposomes to Efficiently Deliver CpG Oligonucleotides in vivo
2/02	E-214-01/0		Novel Method for Rapidly Generating Mature Dendritic Cells from Peripheral Blood Monocytes and Myeloid Precursors
2/02	E-282-01/0		N-Formyl Peptide Receptor Mediation of Platelet Chemotaxis Toward Injured Cells and Activation of Immune Response
2/02	E-339-01/0		Filtration of Red Blood Cells
1/02	E-172-1999		Peptides that Stabilize Protein Antigens and Enhance Presentation to CD8+ T Cells
1/02	E-077-00/0 E-077-00/1		Combined Inhibition of Phosphodiesterase-4 (PDE-4) and Phosphodiesterase-3 (PDE-3) as a Therapy for Th1 Mediated Autoimmune Diseases
1/02	E-002-01/0		Tumor Antigen Homologous to Poly(A) Polymerase
1/02	E-086-2001 E-086-2001		Novel Peptides to a Melanoma Antigen and Their Use in Diagnostic and Therapeutic Methods
1/02	E-295-1999		Gene Involved in Dietary Sterol Absorption and Excretion and Uses Therefor
1/02	E-286-2000		Histone Deacetylase Inhibitors in Diagnosis and Treatment of Thyroid Neoplasms
1/02	E-161-2000		XAGE-1, A Gene Expressed in Multiple Cancers and Uses Thereof
1/02	E-311-2000		Thymidylate Synthase Peptides that Bind to Thymidylate Synthase Messenger RNA
1/02	E-126-01/0		Human Papilloma Virus Immunoreactive Peptides
1/02	E-089-2001		Suppression of CCR5- but not CXCR4-Tropic HIV-1 Replication in Lymphoid Tissue by Human Herpes Virus 6
1/02		6,673,905 7,211,445	A Method for Bioconjugation Using Diels-Alder Cycloaddition
1/02	E-285-2000		LL-37 is an Immunostimulant
12/01	E-167-1999		Utilization of FPRL1 as a Functional Receptor by Serum Amyloid A (SAA)
12/01	E-209-01/0		Neurotrophic Components of the ADNF I Complex
12/01	E-209-2001 E-209-2001 E-209-2001		Neurotrophic Components of the ADNF I Complex
11/01		5,254,539 5,616,566 5,026,687	Method of Treating HIV with 2',3'-Dideoxyinosine (ddI; didanosine)
11/01	E-278-2000		Differentiation of Stem Cells to Pancreatic Endocrine Cells
11/01	E-088-01/0		Diacylglycerol Compounds Useful as Protein Kinase C Activators and Apoptosis Inducers
11/01	E-108-01/0		Side Exit Guiding Catheter for Percutaneous Endomyocardial Injection
10/01	E-172-2000		Development of a Single Vector Containing cre Recombinase and Two Functional lox Sites: Active cre Produced in Eukaryotic but not Prokaryotic Systems
10/01	E-296-2000		Intercellular Delivery of a Herpes Simplex Virus VP22 Fusion Protein from Cells Infected with Lentiviral Vectors
9/01	E-067-2001		Secretion of Native Recombinant Lysosomal Enzymes by Liver
9/01	E-179-01/0		Identification of a Cell-surface Receptor for Papillomaviruses
9/01	E-237-2001		Batrachotoxins as Unique Activators of Sodium Channels
9/01	E-033-01/0		New Isoform of Tyrosinase-Related Protein (TRP-2) that Contains an HLA-A2 Restricted Epitope
9/01	E-141-2000		Agents Useful for Reducing Amyloid Precursor Protein and Treating Dementia and Methods of Use Thereof
9/01	E-175-2001		Methods and Structures for Microengineering Neocartilage Scaffolds
8/01	60/229,842		Sensitization of Cancer Cells to Immunoconjugate-Induced Cell Death by Transfection with Interleukin-13 Receptor Alpha-Chain
8/01	E-193-01/0		Single-Chain Antibody Fragment Protein Binding to HIV-1 Integrase
8/01	60/290,722		Modified Leptin
08/01	E-105-00/0		Method to Fabricate Continuous Lengths of Helical Coiled Shape Memory Wire
08/01	E-123-00/0		Method of Treating Cutaneous T-Cell Lymphoma by Administering a Histone Deacetylase Inhibitor
8/01	E-264-2001		A Mouse Model of von Hippel-Lindau Disease
8/01	E-243-2001		A Mouse Model of Multiple Endocrine Neoplasia, Type I
7/01	E-074-99/7		Glycosylation-resistant Cyanovirins and Related Conjugates, Compositions, Nucleic Acids, Vectors, Host Cells, Methods of Production and Methods of Using Nonglycosylated Cyanovirins
6/01	E-053-2001		PRAC & PRAC-Y: Small Nuclear Proteins Found in Prostate and Colon Cancer, and Uses Thereof
6/01	E-231-00/0		Virus-Like Particles as Unlinked Adjuvants
6/01	E-249-2000		5-Substituted Derivatives of Conformationally Locked Nucleoside Analogues
5/01	E-110-01/0		A Plasmid for Expression of a More Soluble Form of HIV Integrase Protein in E. coli
5/01		6,713,081	Ocular Therapeutic Agent Delivery Devices And Methods
5/01	E-222-2000		Novel Inhibitors of p53 for Treatment of Neurodegenerative Disorders, Myocardial Infarction and Other Tissue Insults
5/01		5,693,779	Production and Use of Anti-Dorsalizing Morphogenetic Protein
4/01		5,861,158	Immunization from an Immunized Allogeneic Bone Marrow Donor
4/01		7,351,580	Use of Endogenous Vertebrate Phytase to Increase Capacity To Utilize Phytic Acid in Livestock Feed
4/01		6,949,624	Cloning of the Human Nuclear Receptor Co-Repressor Gene
4/01	E-276-00/0		A Method of Inhibiting Viral Replication Targeting the Nucleocapsid Protein
4/01	E-237-1999		Methods for Preventing Strokes by Inducing Tolerance to E-selectin
4/01		7,442,212	Decoding Algorithm for Neuronal Responses
4/01	E-188-00/0		Method of Preparing a Production Intermediate for HIV Protease Inhibitors
4/01		6,756,215	Biologically Active FLAG-Epitope-Tagged Transforming Growth Factor Beta (TGF-beta) Protein
3/01	E-144-00/0		GHEP, A Gene Highly Expressed in Normal and Neoplastic Prostate, and Uses Therefor
2/01		6,974,698	Methods for Delivering Biologically Active Molecules into Cells
2/01	E-291-99/0		Efficient Generation of Midbrain Neurons from Mouse Embryonic Stem Cells
2/01	E-186-00/0		Radio Frequency Probes for Tissue Treatment and Methods of Use
2/01	E-001-2001 E-001-2001		Coupled Calcium/Citrate Delivery System and Method for Apheresis Devices
2/01	E-015-2000		Antiprogestins with Partial Agonist Activity
2/01	E-237-2000		RASS1: A Novel Tumor Suppressor Gene Activated by Ras to Promote Apoptosis
2/01	E-165-1999		Potentiation of Antineoplastic Agents Using Sigma 2 Ligands
2/01		6,280,734	Simian-Human HAV Chimeras Encoding a Hepatitis A Virus Having a Chimeric 2C Protein
02/01	E-288-00/0		The ImmunoChip
1/01	E-047-01/0		Ribonuclease H1 - A Protein Expressed in Escherichia coli from a Cloned Human RNase H1 cDNA
12/00	E-123-1999		PTH2 and PTH1 Receptor Ligands
12/00	E-066-2000		Method of Regulating Interleukin-12 (IL-12) Production by Administering CCR5 Agonists and Antagonists
12/00	E-281-2000		A Mouse Model of UV-Inducible Cutaneous Malignant Melanoma
12/00	E-259-00/0		Protein Kinase A and the Carney Complex
12/00	E-243-00/0		Gamma-Glutamyl Transpeptidase Inhibitors: Novel Chemotherapeutic Agents
12/00		6,521,635	Inhibition of MXR Transport by Acridine Derivatives
12/00	E-272-2000		Human Erythropoietin Receptor Transgenic Mice
12/00	E-223-00/0		Transcranial Magnetic Stimulation Coil for Specific Non-Invasive Deep Brain Stimulation
12/00	E-170-2000		NAG-1: A Non-Steroidal Anti-Inflammatory Drug Related Gene Which Has Anti-Tumorigenic Properties
12/00	60/209,067		Peroxynitrite Generators, Compositions Comprising Same, and Methods for Treating Biological Disorders Using Same
12/00	E-129-2000		Gadd45a-Null Mice (45C Clone) and Cells Derived from Them
12/00		7,101,541	Utilization of Non-Viral Sequences for Minus-Strand DNA Transfer and Gene Reconstitution
12/00	E-161-2000		Discovery of Gene Expressed in Many Cancers and Only Normal Testis
12/00	E-192-2000		HCDS1 Kinase Activates Breast Tumor Suppressor BRCA1 and Promotes DNA Damage Repair
12/00	E-194-2000		Methods and Compositions of Viral Chemokine-Antigen Fusion Proteins as Vaccines for Tumors and AIDS
12/00	E-196-2000		Antitumor Immunity Elicited by Defensin-Tumor Antigen Fusions
12/00	E-207-2000		Ixodes Salivary Anticomplement Protein
12/00		7,078,508	Ixodes scapularis Tissue Factor Pathway Inhibitor
12/00	E-014-2000		Secreted Frizzled Related Protein, sFRP, Fragments and Methods of Use Thereof
12/00	E-056-00/0		T-Cell Epitope of MAGE-12 and Related Nucleic Acids, Vectors, Cells, Compositions, and Methods of Inducing an Immune Response to Cancer
12/00	E-090-2000 E-227-2000 E-090-2000		Novel MHC Class II Restricted T Cell Epitopes from the Cancer Antigen, NY-ESO-1 and MHC Class II Restricted CD4+ T Cell Epitopes From NY-ESO-1 Presented by DP
12/00	E-126-2000		A Method for Bioconjugation Using Diels-Alder Cycloaddition
11/00		7,144,734	Enhanced Homologous Recombination Mediated by Lambda Recombination Proteins
9/00	E-061-1999		Polypeptides Comprising IL-6 Ligand Binding Receptor Domains and Related Nucleic Acids, Antibodies, Compositions and Methods
9/00	E-093-2000		Method of Diagnosing Multidrug Resistant Tuberculosis
9/00		6,737,511	Receptor-Mediated Uptake of an Extracellular Bcl-X_L Fusion Protein Inhibits Apoptosis
8/00	E-149-1999		Ichthyosiform Skin Diseases
8/00		6,448,245	HIV Protease Inhibitors, Ritonavir and Saquinavir are Potent Inhibitors of Calcium Activated Neutral Peptidases, Calpains
8/00	E-286-1999		Constitutively Open Voltage-Gated K+ Channels and Methods for Discovering Modulators Thereof
8/00	E-277-98/0		Delivery of Proteins Across Polar Epithelial Cell Layers
7/00	E-068-2000		Molecules That Influence Pathogen Resistance
7/00		7,132,392	Inhibition of Cell Motility
7/00	E-245-99/0		Polypeptides that Bind HIV gp120 and Related Nucleic Acids, Antibodies, Compositions, and Methods of Use
7/00	E-087-2000		Establishment of Cellular Manipulations Which Enhance Oligo-Mediated Gene Targeting
7/00	E-243-1999		Fibroblast Growth Factor-5 (FGF-5) is a Tumor Associated T-cell Antigen for Human Renal Cell Cancer and Other Adenocarcinomas
7/00	E-062-2000		A Novel Pro-Apoptotic Protein, ARTS
6/00		6,419,639	Laparoscopic Sac Holder Assembly
6/00	E-072-99/0 E-072-99/1		Transition Metal Complexes of N,N',N''-trialkyl-cis,cis-1,3,5-triaminocyclohexane and Related Compositions and Methods
6/00	E-032-99/1		Direct C-14 Oxidation of Opioids
5/00		6,881,718	Novel Disulfide Conjugated Cell Toxins and Methods of Making and Using Them
4/00	E-257-1999		Methods and Compositions for Correlating CCR5 Expression with Essential Hypertension
4/00		6,855,323	Identification of the Domain of Plasmodium falciparum Erythrocyte Membrane Protein (PfEMP1) that Mediates Adhesion to Chondroitin Sulfate A
4/00		5,489,525	Monoclonal Antibody Specific to Prostate Cells
4/00		6,441,156 6,979,724	Calcium Channel Compositions and Methods of Use Thereof
1/00		6,743,626	Artificial Salivary Gland
10/99		6,613,764 7,132,420	Aspartic Protease Inhibitors, Compositions, and Associated Therapeutic Methods
10/99		5,728,718 5,925,780 6,066,656	2,5-diamino-3,4-disubstituted-1,6-diphenylhexane Isosteres Comprising Benzamide, Sulfonamide and Anthranilamide Subunits and Methods of Using
9/99	E-076-1999		Acetylated and Related Analogues of Chicoric Acid as HIV Integrase Inhibitors
9/99	60/108,903	9,927,341	Identification of Globotriaosylceramide as a Promoter of HIV-1 Entry into Cells
9/99	60/141,072		Antiviral Genetic Target Within HIV gag-pol Transframe Region
9/99	60/141,701		Human Monoclonal Antibodies to HIV-1 Envelope Glycoprotein gp120
9/99		6,613,318 7,005,419 7,125,850	Methods For Identifying Modulators Of GADD45 Polypeptide Activity
9/99	E-271-1998		Methods For Treating Tumors Using Anti-Angiogenic Compounds
9/99		6,686,333	Inhibition of HIV Replication Using Soluble Tat Peptide Analogs
9/99	09/313,487		Identification and Use of High Efficacy Vaccine Antigens Which Modulate Antigen Presenting Cells
9/99		6,057,346	Inhibition of Retroviral LTR Promoters by Calcium Response Modifiers
9/99		6,316,190	Oligonucleotides Which Specifically Bind Retroviral Nucleocapsid Proteins
8/99		6,323,316 6,608,181 6,831,170	Fibroblast Growth Factor Receptor Activating Gene 1 (FRAG1), Related Proteins and Methods
8/99		7,129,052	Peptides and Their Utility in Modulation of Behavior of Cells Expressing alpha3beta1 Integrins
8/99		4,923,970	A New Class of Anti-Tumor Agents
8/99	60/094,690		Thymosin ß4 Promotes Wound Repair
8/99		5,857,309 5,888,705	Methods of Stimulating Proliferation and Differentiation of Human Pancreatic Cells Ex Vivo
8/99	E-176-1998		Apoptosis Inducing Agents and Methods
8/99		7,226,991	Phenylalanine Derivatives
7/99	E-068-1999		UPA, A Universal Protein Array System For Quantitative Detection Of Protein-Protein, Protein-DNA, Protein-RNA And Protein-Ligand Interactions
7/99		6,479,465	Methods of Treating Colitis Using STAT-4 Antisense Oligonucleotide
7/99		6,696,551 6,995,247	Ac-HEHA and Related Compounds, Methods of Synthesis and Methods of Use
7/99	E-121-99/0		Methods For Mitochondrial Gene Therapy
7/99	09/271,009		Low Level Exposure To Extract Of Neurotoxin For Protection From Brain Injury
7/99		5,998,598	Immunoadhesins and Methods of Production Thereof
6/99		5,843,882 6,015,876	Cyanovirin-Based Topical Microbicides For Prevention Of Sexual Transmission Of HIV
6/99		6,677,314 6,677,315 6,753,309	Nucleosides for Imaging and Treatment Applications
6/99		6,596,269	Virally Mediated Gene Therapy For The Control Of Chronic Or Persistent Pain
6/99		6,610,660 6,911,433 7,081,524	O²-Arylated or O²-Glycosylated 1-Substituted Diazen-1-ium-1,2-diolates and O²-Substituted 1-[(2-Carboxylato)Pyrolidin-1-yl] Diazen-1-ium-1,2-diolates
6/99		6,307,090	Acylated Oligopeptide Derivatives Having Cell Signal Inhibiting Activity
6/99		6,238,858	Transgenomic Viruses
6/99		6,423,696	Modulation of N-Acetyl-Transferase to Improve Therapy and Prevent Cancer
6/99	60/119,114		Identification of the Geldanamycins as Inhibitors of the HGF/SF-Met-uPA Proteolytic Network
6/99	60/113,423		Water-Insoluble Drug Delivery System
6/99	E-282-1998		Antagonists of the Alpha Epsilon Beta 7 Integrin as Therapeutic Agents for Inflammatory Diseases
6/99		5,562,905	Immunologically Active Peptides From The HIV Envelope Protein Eliciting Both Antibody And T Cell Responses
6/99	60/097,446	9,918,674	Modified HCV Peptide Vaccine
5/99		6,221,620	Monoclonal Antibodies Specific for Human Thymidylate Synthase
4/99	E-175-1998		Human Cancer Antigen TRP2
4/99	E-157-94/1		Method and Composition for Detecting Dihydropyrimidine Dehydrogenase Splicing Mutations
4/99		5,849,691	Peptidomimetic Inhibitors of Cathepsin D and Plasmepsins I and II
4/99		5,872,210	Transframe Peptide Inhibitor Of Viral Protease
3/99		6,316,423	Method of Treating Ischemic, Hypoxic, and Anoxic Brain Damage
3/99	E-006-98/0		Methods and Compositions for Reducing Ischemic Injury of the Heart by Administering Adenosine A3 and Adenosine A1 Receptor Agonists
3/99	08/813,787		Methods and Compositions for Protecting Against Cardiac Ischemia by Administering Adenosine A2a Receptor Antagonists
3/99		6,485,925	Anthrax Lethal Factor is a MAPK Kinase Protease
3/99	E-301-1998 E-301-1998 E-301-1998	6,630,124	Combination Therapy With VIP Antagonists
3/99		5,645,988	Method of Identifying and Using Drugs with Selective Effect Against Cancer Cells
3/99		6,552,181	A Basal Cell Carcinoma Tumor Suppressor Gene
2/99		6,867,180	Use Of Calreticulin And Calreticulin Fragments To Inhibit Endothelial Cell Growth And Angiogenesis, And Suppress Tumor Growth
2/99	E-130-97/1		Polynucleotide Inhibition Of RNA Destabilization And Sequestration
2/99	E-196-1998 E-196-1998		Pressure Mediated Selective Delivery Of Therapeutic Substances
2/99		6,719,978	Chimeric Virus-Like Particles For The Induction Of Autoantibodies
2/99		6,458,590	Methods and Compositions for Treatment of Restenosis
2/99	E-196-1998 E-196-1998 E-196-1998		Pressure Mediated Selective Delivery Of Therapeutic Substances
2/99		6,787,356	Cell Expansion System For Use In Neural Transplantation
2/99		5,942,433 6,361,968	Extension Of A Protein-Protein Interaction Surface To Inactivate The Function Of A Cellular Protein
1/99	09/023,726	6,060,458	Oligodeoxyribonucleotides Comprising O6-Benzylguanine and Their Use
01/99	09/128,450 09/823,494	6,211,149	Inhibitors of Formation of Protease Resistant Prion Protein
1/99		5,474,935	Adeno-Associated Virus (AAV)-Based Eucaryotic Vectors
1/99	60/076,330 09/623,000	9,904,002	Disubstituted Lavendustin A Analogs And Pharmaceutical Compositions Comprising the Analogs
1/99		7,029,899	Amino-Terminus-Modified Eosinophil-Derived Neurotoxin and Its Selective Toxicity to Kaposi's Sarcoma Cell Line, KS Y-1
12/98		6,492,166	Use of Constitutive Transport Elements to Control the Host Range of Retroviral Vectors
12/98	60/096,148	9,918,297	Inhibitors Of Formation Of Transmissible Spongiform Encephalopathy- Associated Prion Protein By Porphyrins And Phthalocyanines
12/98		6,534,626	Chemokine Variants And Methods Of Use
12/98		6,197,751	Thymosin alpha 1 Promotes Tissue Repair, Angiogenesis and Cell Migration
12/98		6,326,466	Double-Stranded RNA Dependent Protein Kinase Derived Peptides To Promote Proliferation Of Cells And Tissues In A Controlled Manner
12/98	E-032-96/1		Infectious Papillomavirus Pseudoviral Particles
12/98		5,720,892 5,824,520	Method of Inhibiting the Activity of an Intracellular Constituent
12/98	E-066-1996		AAV4 Vector And Uses Thereof
11/98		6,562,859	Ureido Derivatives Of Poly-4-Amino-2-Carboxy-1-Methyl Pyrrole Compounds For Treatment Of Inflammation
11/98		4,892,827	Drug and Method for the Therapeutic Treatment of Primary Brain Tumors (Such As Intracranial Human Glioma, Astrocytomas, Medulloblastomas and Metastatic Tumors to the Central Nervous System)
10/98		5,455,251 5,654,432	Michellamine Antiviral Agents, Compositions, And Treatment Methods
10/98		5,552,550 5,763,613	Monomeric Naphthylisoquinoline Alkaloids And Synthesis Methods Thereof
10/98		5,571,919 5,789,594	Dimeric Naphthylisoquinoline Alkaloids And Synthesis Methods Thereof
10/98		5,409,938	Antimalarial Korupensamines And Pharmaceutical Compositions And Medical Uses Thereof
10/98		5,639,761 6,627,641	Antimalarial Napthylisoquinoline Alkaloids And Pharmaceutical Compositions And Medicinal Uses Thereof
10/98		6,365,712 6,846,911	Methods And Compositions For Inhibiting Inflammation And Angiogenesis
10/98		6,068,844	The Application Of Induction Tolerance By Oral Feeding Of Myelin Basic Protein To The Generation Of Increased Resistance To Stroke
10/98		6,140,339 6,331,630	Monomeric And Dimeric Arylisoquinoline Alkaloids And Derivatives Thereof
10/98		5,578,729 5,786,482	Dimeric Arylisoquinoline Alkaloids And Synthesis Methods Thereof
10/98		6,630,507	Cannabinoids As Neuroprotectants
9/98	E-174-1997		Protection Of Tissue From Ischemic Damage
9/98		6,747,055	Water Soluble Drugs and Method of Preparing Same
9/98		6,084,063 6,353,097	Signal Transduction Inhibitors Of Allergic Reactions
9/98	60/076,293 09/643,548	9,900,967	Therapeutic Blockage of ICER Synthesis to Prevent ICER-Mediated Inhibition of Immune Cell Activity
9/98	60/075,994	9,904,336	Inhibition Of HFG/SF Cleavage/Activation By Suramin And Other Related Small Molecules
9/98		7,105,488	G-Protein Coupled Receptor Antagonists
9/98	60/076,293 09/643,548	9,900,967	Therapeutic Blockage of ICER Synthesis to Prevent ICER-Mediated Inhibition of Immune Cell Activity
9/98	E-166-1998		LIF And Related Cytokines That Operate Through The gp130 Receptor Pathway As A Means To Enhancing Embryo Implantation In Mammals And As An Alternative To Using Estrogen
9/98	60/094,246		Protection Of Neural Cells From Catecholamine-Induced Apoptosis By Macrophage Migration Inhibitory Factor (MIF)
9/98		6,046,228	Anti-Viral Pharmaceutical Compositions Containing 1,2-Dithiane Compounds And Methods Of Using Thereof
7/98	E-013-1996		Compound, Composition, and Method for Treating Cancer
7/98	E-070-97/0		Cloning Of GMEB 1 And 2: Two Proteins Involved In The Modulation Of Glucocorticoid Regulated Gene Transcription
5/98		6,313,090	Methods For Treating Parasitic Infection Using Thiopeptides
3/98	09/124,955		CC Chemokine Receptor 8 DNA, New Animal Models and Therapeutic Agents for HIV Infection
3/98		6,084,099 6,277,980	Human Papilloma Virus Inhibition By Antisense Oligonucleotides
03/98	09/402,275		STRL33, A Human Fusion Accessory Factor Associated With HIV Infection
3/98		6,600,030	Delayed Progression To AIDS By A Missense Allele Of The CCR2 Gene
3/98		6,383,746	Functional Promoter For CCR5
1/98	E-032-1997		Method Of Promoting Tumor Necrosis Using MIG
1/98		5,914,121	Formation Of Human Bone In Vivo
12/97	60/033,918	9,800,784	Enhanced Suppression Of HIV-1 by the Combination of Cytidine Dideoxynucleoside Analogues And CTP Synthase Inhibitors
11/97		6,627,745	Identification Of The Gene Causing Familial Mediterranean Fever
11/97		6,426,070	Methods For Inactivating Enveloped RNA Virus Particles And Compositions For Use Therewith
10/97		6,562,589 7,232,890	AIB-1, A Steroid Receptor Co-Activator Amplified In Breast And Ovarian Cancer
10/97		6,861,415	21-Substituted Progesterone Derivatives As New Antiprogestational Agents
10/97		6,689,560	raf Protein Kinase Therapeutics
10/97		5,514,539 5,871,962 6,572,864	Diagnostic Reagents And Vaccines For Multiple Genotypes Of Hepatitis C Virus
10/97		5,092,885	Peptides With Laminin Activity
8/97	E-011-97/0		Transgenic And Chimeric Viral Delivery Systems
8/97		7,358,347	MEN1, The Gene For Multiple Endocrine Neoplasia Type 1
5/97		6,884,871 6,924,367 7,049,291	Isolation And Use Of Tissue Growth-Inducing FRZB Protein
5/97		5,840,839 6,097,110 5,831,016	Novel Human Cancer Antigen of Tyrosinase-Related Proteins 1 and 2 and Genes Encoding Same
5/97	08/618,936		Prostate Specific Antigen Oligo-Epitope Peptide
5/97		5,449,608	Parvovirus B19 Receptor And Parvovirus B19 Detection
5/97		5,656,737	Macrophage Migration Inhibitory Factor (MIF)
05/97	60/030,999	9,721,723	Vanilloid Agonists for Desensitization of C-Fiber Sensory Afferent Neurons
5/97		6,387,389	Sustained-Release Derivatives of Hydroxylated Analogs of Substituted 1- [2[bis(aryl)methoxy]-ethyl] -Piperazines and -Homopiperazines and Their Use as Noncompetitive Antagonists of Dopamine Reuptake Inhibitors
4/97		5,637,323	Method Of Mobilizing Pluripotent Hematopoietic Stem Cells And Accelerating Leukocyte Reconstitution With IL-7
1/97		6,780,413	Immunotoxin (MAB-RICIN) For The Treatment Of Focal Movement Disorders
1/97	E-131-2994		Substantially Pure Non-IL-2 T-Cell Growth Factors
1/97		6,156,765	2,2'-Bipyridyl, a Ferrous Chelator, Prevents Vasospasm in a Primate Model of Subarachnoid Hemorrhage
1/97		5,830,755	T-Cell Receptors And Their Use In Therapeutic And Diagnostic Methods
1/97	08/172,664	5,674,492	Method Of Preventing Or Treating Disease Characterized By Neoplastic Cells Expressing CD40
1/97		6,951,917	MHC Class II-Restricted Melanoma Antigens And Their Use In Therapeutic Methods
12/96		6,391,651 5,989,551	Materials And Methods For Detection And Treatment Of Insulin Dependent Diabetes
12/96		5,792,775	4'- And 4',4"-Substituted-3alpha(diphenylmethoxy)tropane Analogs As Cocaine Therapeutics
12/96		5,428,154	Macrocyclic Chelates, and Methods of Use Thereof
11/96	60/023,931 09/242,202	9,714,306	A Novel Vector for Polynucleotide Vaccines
11/96	E-088-1996		Point Mutated ras Peptides for the Generation of CD8+ Cytotoxic T Lymphocytes
11/96	09/185,408		Glycoprotein Hormone Superagonists
11/96		6,197,578	Cells Expressing Both Human CD4 And A Human Fusion Accessory Factor Associated With HIV Infection
10/96		5,317,009	Anti-HIV Proteins GAP 31, DAP 30 And DAP 32 And Therapeutic Uses Thereof
10/96		5,532,214	An Anti-HIV Protein, TAP 29, From Trichosanthes, DNA Coding Therefor And Therapeutic Uses Thereof
10/96		5,484,889	Plant Protein Useful For Treating Tumors And HIV Infection
9/96	06/481,934	4,565,789	Cell Matrix Receptor System And Use In Cancer Diagnosis And Management
8/96		5,405,782	A Detection Device and Quantification Method for Therapeutic Agents in Blood
8/96		5,677,275 5,877,148	Treatment Of Cancer With Human Chorionic Gonadotropin
8/96		5,571,156	Method For In Situ Testing Of Integrity Of Electrical Stimulator Leads
8/96		5,678,550	Apparatus And Method For The In-Situ Detection Of Areas Of Cardiac Electrical Activity
8/96		5,763,464	Novel Retroviral Agents Containing Anthranilamide, Substituted Benzamide And Other Subunits, And Methods Of Using Same
7/96		5,853,697	Methods Of Treating Established Colitis Using Antibodies Against IL-12
7/96		5,183,884 5,480,968 5,820,859	Novel Epidermal Growth Factor Receptor (ErbB-3) And Antibodies
7/96		6,319,687	Pigment Epithelium Derived Factor: Characterization, Genomic Organization and Sequence of PEDF Gene
7/96		5,526,395	System And Method For Simulating A Two-Dimensional Radiation Intensity Distribution Of Photon Or Electron Beams
7/96		6,566,098	Truncated Hepatocyte Growth Factor Variants
7/96		5,840,686	Pigment Epithelium Derived Factor: Characterization of Its Novel Biological Activity and Sequences Encoding and Expressing the Protein
7/96		5,578,566	Peptide Antagonist Of Keratinocyte Growth Factor Activity
7/96	08/004,936 08/858,248 08/858,925	5,837,477 5,948,409 5,958,712	T Cell Receptor Ligands, And Methods For Use
7/96		5,219,991 5,527,685	Macrophage Stimulating Protein
7/96	06/724,897	4,707,443	Soluble Interleukin-2 Receptor As A Disease Indicator And A Method Of Assaying The Same
7/96		5,352,772	75 Kilodalton Interleukin-2 Receptor Proteins And Their Use
4/96	E-131-1991		Adenovirus Mediated Transfer Of Genes To The Gastrointestinal Tract
4/96		5,439,899	Cosalane And Related Compounds Having Activity Against AIDS And AIDS-Related Infections
4/96		5,672,593 5,731,301 5,808,038	Bistriazenes as Chemotherapeutic Agents
4/96		5,518,558 5,654,406	ERBB2 Promoter Binding Protein In Neoplastic Disease
4/96		5,716,788 5,763,216	A Gene Encoding a Human Reduced Folate Carrier (RFC) and Methods for the Treatment of Methotrexate-Resistant, Transport-Deficient Cancer Cells
4/96	08/445,462		Avian Based Retrovirus Vectors
4/96		5,532,144	Human Derived Monocyte Attracting Purified Peptide Products For Treating Human Infection And Neoplasms
4/96		5,994,292	Interferon-Inducible Protein 10 Is A Potent Inhibitor Of Angiogenesis
4/96		5,990,088	Method For Treatment Of Kaposi's Sarcoma (KS) By Antisense Oligonucleotides
4/96		6,265,160	Method Of Identifying Inhibitors Of The Jak-STAT Signal Transduction Pathway
3/96		5,780,589	Application of Highly Potent and Ultraselective delta Opioidmimetic Peptide Antagonists for Biochemical, Pharmacological, Clinical and Therapeutic Studies
2/96	08/083,945 07/827,043		AAMP-1
2/96		5,593,966	Peptide Derivatives Of Cytochrome b558 And Their Use As Medicaments [As Anti-Inflammatory Agents]
2/96		5,681,832	Amido Substituted Stilbenes And Related Compounds With In Vitro Anti-HIV Activity
2/96	08/479,039	5,663,167	Antipsychotic Composition And Method For Treatment
2/96		5,556,754 5,871,950	Methods For Treating Autoimmune Diseases And Transplantation Rejection
6/95		5,658,146	An Improved Dental Abutment-Prosthesis Fastener
6/95		5,519,534	An Integrating Sphere Which Delivers A Homogeneous Beam Of Laser Light For Use In Photodynamic Therapy
5/95	E-134-1994		Hepatitis C Virus Core Peptide For Stimulation Of Cytotoxic T Lymphocytes
5/95	08/133,574 08/319,888 08/814,228	5,650,442 5,837,736	Nitric Oxide-Releasing Compounds As Hypoxic Cell Radiation Sensitizers
11/94		5,516,630 5,849,562	Production Of Complementary DNA Representing Hepatitis A Viral Sequences By Recombinant DNA Methods And Uses Therefor
11/94		5,610,198	Novel Anti-Mycobacterial Compositions and Their Use for the Treatment of Tuberculosis and Related Diseases
11/94		5,386,021 5,514,600	Mammalian Guanine Nucleotide-Binding Protein with an ADP-Ribosylation Factor Domain (ARD1)
11/94	08/188,325	5,483,958	Fluorescent-Tipped Dosimeter Probe
11/94		5,441,530 5,527,349	Photochemotherapy Dosimeter
11/94		5,498,719	Diastereoselective Process Leading To A Key Intermediate For The Preparation Of Fluorinated Reverse Transcriptase Inhibitors
11/94		5,711,296 5,429,127 5,305,740	Continuous Positive Airway System
11/94		5,716,816	Clones Encoding Mammalian ADP-Ribosylarginine Hydrolases
1/94		5,437,951 5,756,284 5,709,996	Self-Assembling Recombinant Papillomavirus Capsid Proteins
12/93		5,468,468 5,863,739 5,833,986	Neutralizing Monoclonal Antibody To Human Alpha PDGF Receptors
12/93		5,720,720	Convection-Enhanced Drug Delivery System
11/93		5,518,880 5,912,173	Methods for Diagnoses and Treatment of XSCID
4/93	08/330,865	6,060,334	Anticancer Activity of Lovastatin and Related Compounds
12/91		5,474,089	Method And Device For Reversible Sterilization
1/91		4,968,690 4,975,434	3-Deazaneplanocin, Intermediates for It, and Antiviral Composition and Method of Treatment Using It

Back